Rochester Institute of Technology

RIT Scholar Works
Theses
5-2020

Modular Synthesis of Dual- and Tri-modal Targeted Molecular
Imaging Agents
Nicholas C. Schug
ncs2414@rit.edu

Follow this and additional works at: https://scholarworks.rit.edu/theses

Recommended Citation
Schug, Nicholas C., "Modular Synthesis of Dual- and Tri-modal Targeted Molecular Imaging Agents"
(2020). Thesis. Rochester Institute of Technology. Accessed from

This Thesis is brought to you for free and open access by RIT Scholar Works. It has been accepted for inclusion in
Theses by an authorized administrator of RIT Scholar Works. For more information, please contact
ritscholarworks@rit.edu.

Modular Synthesis of Dual- and Tri-modal
Targeted Molecular Imaging Agents

Nicholas C. Schug
A thesis submitted in partial fulfillment of the requirements for the degree
Master of Science in Chemistry

Supervised by
Dr. Hans Schmitthenner
School of Chemistry and Materials Science
College of Science
Rochester Institute of Technology
May 2020

Signature of the Author ______________________________

Accepted by _______________________________________
Director, M.S. Degree Program
Date

i

SCHOOL OF CHEMISTRY AND MATERIALS SCIENCE
COLLEGE OF SCIENCE
ROCHESTER INSTITUTE OF TECHNOLOGY
ROCHESTER, NEW YORK
CERTIFICATE OF APPROVAL
_____________________________________________________________________
M.S. DEGREE THESIS
_____________________________________________________________________

The M.S. Degree Thesis of Nicholas C. Schug has
been examined and approved by the thesis
committee as satisfactory for the thesis required
for the M.S. Degree in Chemistry.

_________________________________________
Dr. Hans Schmitthenner, Thesis Advisor
_________________________________________
Dr. Nathan Eddingsaas
_________________________________________
Dr. Joseph Hornak
_________________________________________
Dr. Michael Pierce
___________________________
Date

ii

Abstract
There are few reported methods for combining two or three different imaging
dyes, metals, or dye-metal combinations, followed by the conjugation of a diseasetargeting group to enable the use a given imaging system for multiple imaging
applications. Previously, peptides have been used as scaffolds for dyes and metals used
in diagnostic techniques such as optical molecular imaging (OMI), positron emission
tomography (PET), and magnetic resonance imaging (MRI). The aim of this project was
to reassemble peptide-based imaging agents through a modular method by coupling
together modules comprised of amino acids with imaging agents attached to their side
chains to form “imaging peptides,” followed by attaching a cancer-targeting group in the
final step. This new modular approach for the synthesis of a diverse set of targeted
molecular imaging agents (TMIAs) was optimized and exemplified by the synthesis of
dual modal PET-MRI, dual OMI-MRI and dual metal (di-gadolinium for MRI), and the
partial synthesis of a tri-modal OMI-PET-MRI agent. The dual modal imaging peptides
were conjugated through a linker to targeting groups for lung cancer (A549 cells) and
prostate cancer (PSMA positive C4-2) cells. In addition to imaging applications for early
detection, active surveillance, image guided biopsies and surgery, this modular approach
could potentially be used for creating therapeutic agents to treat cancer patients.
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1. Introduction
1.1. Cancer
Cancer refers to a group of diseases that are characterized by the uncontrolled
growth and spread of abnormal cells. If left untreated, cancer is likely to result in death.
More than 1.7 million new cancer cases were expected to be diagnosed in 2019 in the
U.S. and approximately 606,880 Americans were expected to die of cancer in 2019.1
This translates to roughly 1660 deaths per day, making cancer the second most common
cause of death in the United States, exceeded only by heart disease. Although our
understanding and knowledge of cancer and its treatment methods continues to grow2, the
number of new cancer cases per year is also growing.3 Due to the ever-growing societal
impact of cancer, improving cancer detection and treatment methods remains to be an
important scientific research endeavor.
There are many different types of cancer. The commonality between all the
different types is that cancer cells divide without stopping and begin to spread into
surrounding tissues in the body.4 Cancer can start in almost any of the trillions of cells in
the body, but usually begins in the more vulnerable tissue of the organs. When cancer
develops, the typical orderly process of healthy cells growth breaks down. This causes
old or damaged cells to survive when they should die and uncontrollably replicate into
new cells. These extra cells will divide without stopping and form tumors. This makes
cancer a genetic disease, since it causes changes in the DNA that, in turn, controls the
way our cells function. Due to the nature of cancer and the way that it grows as its cells
divide, it can sometimes be an extremely difficult or impossible disease to treat.
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There are many different types of treatment methods used to combat cancer. Each
method has varying levels of side-effects and the treatment method utilized typically
depends on the type of cancer and how severe it is.5 Three of the most common
treatment methods are surgery, radiation therapy, and chemotherapy. In surgery, a
surgeon physically removes cancer from the body. Radiation uses high doses of radiation
to irradiate cancer cells and to shrink tumors. Chemotherapy uses potent drugs to kill
cancer cells.5 In most cases, each of these treatment methods have a significant physical
toll on the human body and are not always successful in eliminating the disease. In
addition to these three most common and well-known methods, there are other methods
of

treatment

including

immunotherapy

and

photodynamic

therapy

(PDT).6,7

Combinations of these different treatment methods are often used to increase the success
and decrease the likelihood that the cancer returns.
Screening for cancer is an extremely important medical diagnostic tool. This
refers to testing individuals who have no symptoms or early symptoms of cancer. Early
detection has proved to reduce mortality from cancers of the colon and rectum, breast,
uterine cervix, prostate, and lung.8,9 Early treatment of the disease is the most effective
way to increase the chance of survival as it makes treatment methods more effective.
Unfortunately, without early detection, most cancer treatments occur at a relatively
advanced stage. Because cancer cells can quickly form tumors and spread if untreated,
early diagnosis is important, to allow medical professionals to promptly begin treatment
of the cancer.
Molecular imaging is a widely-used detection method that can be used in the
diagnosis of cancer and provides the greatest hope for curing cancer. By targeting
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specific biomarkers in cancer cells, molecular imaging that utilizes targeted molecular
imaging agents (TMIAs) may vastly increase the effectiveness and success of cancer
detection. The goal of this research project was to develop a synthetic route that other
researchers and manufacturers can utilize to provide a wide variety of TMIAs. This new,
easier and robust method could provide tailor-made TMIAs that could potentially be used
in the diagnosis of many types of cancer with the overall goal of improving cancer
detection which would ultimately decrease the mortality rate due to cancer.
1.2. Molecular Imaging Methods Relevant to Cancer Detection
Currently, there are limited methods used to screen for cancer. Methods can be
invasive, such as a biopsy, where cell tissue is physically removed from a person’s body
to test for the presence of the disease.

In contrast, non-invasive methods such as

molecular imaging prove to be more desirable in screening for cancer as they do not
involve the surgical removal of tissue in the body which can be painful and carries risk of
infection and other factors.10
There is conventional imaging with no contrast agents or non-targeted agents used
in imaging methods such as PET and MRI. While these may detect large tumors, these
methods are not ideal for the detection of cancer in its early stages.
The most common molecular imaging methods which employ contrast agents
used in the detection and diagnosis of cancer are MRI, PET, computed tomography (CT),
optical molecular imaging (OMI), also known as fluorescence imaging) ultrasound
imaging, and x-ray imaging.11–13 The integration or fusion of two imaging methods
together can lead to a more effective imaging method. Instruments are currently available
for two modes of imaging. For example, a combined PET/CT scanner is one of the most
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frequently used instruments in the field of oncology.14 In a PET/CT, images are obtained
separately and combined together using digital processing.

This combination of

instrumentation provides more information than one image and can provide higher image
quality since there are two complimentary imaging methods being fused together.
Precise imaging is essential in determining the best method of treating the cancer
and molecular imaging methods allow radiologists to precisely locate cancerous cells and
determine how far cancer has spread. Although imaging methods can be accurate in their
imaging of the tissues inside the body, it is sometimes difficult to distinguish healthy
tissue from cancerous tissue cells. For cancer detection to be accurate, it is important that
molecular imaging methods are reliable and can consistently provide an accurate picture
of the cancer in the body.
1.3. Targeted Molecular Imaging Agents
In order for cells to be imaged with a high signal-to-background (signal-to-noise)
ratio, targeted imaging agents can be used to increase the visibility of the diseased cells.15
This allows cancerous cells to be more easily differentiated from healthy cells, even when
there is a small amount of diseased cells. Targeted molecular imaging agents (TMIAs)
are the best means of providing better contrast of the disease to improve the overall
quality of the image.9,16
Targeting peptides have been previously coupled with imaging agents (e.g.
radiometals and fluorophores) using different chemical techniques in order to create
TMIAs.15 These imaging peptides, when coupled with separate cancer-targeting moieties,
proved to be extremely effective in the early detection and diagnosis of cancer. This is
due to the fact that cancer targeting compounds are able to target cancer cells selectively
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and with high affinity.17 Since the imaging peptides are connected to the cancer-targeting
moiety, the imaging agents will be in a high concentration due to specific localization in
the cancerous cells only. When appropriate molecular imaging techniques are used to
detect the imaging agents, only the cancerous cells become illuminated and are thus more
accurately distinguished compared to the background, neighboring tissues, or other
artifacts in the image.
Figure 1 shows a schematic of how a TMIA is able to selectively target a receptor
on a tumor cell membrane using the receptor targeting biomolecule. Since the receptor
targeting biomolecule is attached to an imaging agent (the radioactive 64Cu atom in this
case), the cancer can be detected using PET. This image with illuminated cancer cells is
seen in the top left of Figure 1.

Figure 1. Schematic of a TMIA being used in PET showing a targeting biomolecule attached to a
PET imaging agent binding to a tumor receptor on the membrane of a cancer 18
Reprinted with permission from Shokeen, M.; Anderson, C. J. Molecular Imaging of Cancer with Copper-64 Radiopharmaceuticals
and Positron Emission Tomography (PET). Acc Chem Res 2009, 42 (7), 832–841. https://doi.org/10.1021/ar800255q. Copyright 2009
American Chemical Society.
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1.4. Cancer Targeting Groups
TMIAs would not possibly be able to target cancer without having affinity for
cancer cells. In the early years of molecular imaging, scientists found that there are
certain peptides that target biomarkers found in cancerous cells. The most widely used
peptide for this purpose for many years was the cyclic peptide c(RGDyK). This peptide
contains the RGD peptide sequence, known to have a strong affinity for the avb3 integrin
that is overexpressed in many different cases of cancer, such as melanoma, ovarian, lung,
and breast cancer.19 Integrin proteins are critical for self-adhesion of cells in cancerous
tissue and it is also a biomarker in plaques that form in blood vessels due to
atherosclerosis. The chemical structure of c(RGDyK) is shown in Figure 2.

Figure 2. c(RGDyK), a well-known cancer targeting peptide

Due to the preferential binding of the RGD peptide to cancerous cells, it proves to
be a promising method for the delivery of anticancer drugs and contrast agents for cancer
therapy and diagnosis.19 This peptide was the first targeting agent that was used by the
Schmitthenner Molecular Imaging Lab (MIL) at Rochester Institute of Technology
(Figure 3), where c(RGDyK) in red was directly bound to the Cy 5.5 dye (in green) and
used for confocal fluorescence microscopy (CFM) of A549 lung cancer cells.
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Figure 3. c(RGDyK)-Cy 5.5 TMIA (left) and CFM image of lung cancer cells targeted by the
TMIA (right). There are about ten cells shown in this image, with the heart shaped cell in the
middle as an example. The red color is a result of targeting by the TMIA, which is engulfed and
accumulates in each cell by the process of endocytosis.

A second, more recently discovered cancer targeting compound of interest in our
molecular

imaging

laboratory

is

the

peptidomimetic

inhibitor

N[N-[(S)-1,3-

dicarboxypropyl]carbamoyl]-(S)-lysine, which is abbreviated as DCL. DCL targets the
prostate-specific membrane antigen (PSMA) receptor which is overly expressed in
aggressive forms of prostate cancer (PCa). DCL was designed after the three dimensional
X-ray structure of was determined, as an inhibitor of the active site. This makes DCL
extremely effective in the targeting PCa and in wide use currently.20,21 A method for the
synthesis of this urea-based moiety shown in Figure 4, to be used in targeting PCa has
been developed in our group as well.22

Figure 4. DCL urea-based PSMA inhibitor
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Prior to the breakthrough of small-molecule TMIAs in 2008, the main targeting
agent used in clinical diagnosis of PCa by PET was the antibody based ProstaScint®.23
ProstaScint® presented challenges and was unreliable due to low plasma clearance, long
circulation times which resulted in high-background signal, limited tissue penetration,
and restriction of molecular binding to the intracellular domain of cancer cells.22,24
When creating TMIAs, it is important to consider the wide variety of different
cancer targeting agents that can be used in the molecule that is being synthesized. Our
group currently uses a modular synthetic approach, where the imaging agents (dyes,
radioactive metals, etc.) are created first and the cancer agent is added to the molecule in
the final steps of the synthesis. This provides an enormous advantage as it makes it
possible to combine a given modular imaging system with a variety of different targeting
agents to be used for a wide variety of different cancer types.
1.5. Relevant Imaging Agents
There are many different imaging methods that are currently utilized in the
detection and examination of cancer cells including MRI, CT, PET, and CFM. Each
method visualizes cancer cells with varying levels of effectiveness (e.g. contrast of the
cells). The imaging agents discussed in this chapter are not a comprehensive review of
all imaging agents, but are a summary of those types of agents that are most prominent in
our research. Each imaging method uses different physical parameters to obtain an image
and each has unique advantages or disadvantages over other methods. By combining
imaging modalities, we can often combine aspects that are advantageous. By combining
agents for each of those modalities into one molecule we can provide further
improvements to molecular imaging methods.
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1.5.1. MRI Imaging Agents
MRI functions by detecting energy released from protons in the body as they
align with the magnetic field of the instrument then relax to their ground states.25 MRI
imaging (contrast) agents are either ferromagnetic or paramagnetic agents. These agents
work by shortening the relaxation times of the nuclei within the body. MRI is sensitive
to different relaxation times (T1 and T2). The T1 relaxation time (spin-lattice relaxation
time) is a measure of how quickly the net magnetization vector recovers back into the
field of the MRI magnet. The T2 relaxation time (spin-spin relaxation time) refers to the
time required for the decay of the magnetization that is transverse to the field of the MRI
magnet.

These relaxation times are the basis for which an MRI instrument makes

measurements.

Gadolinium(III) (Gd3+)

may enhance those relaxation times and is

therefore one of the most common and widely used paramagnetic contrast agents used in
clinical and pre-clinical (animal studies) MRI.26
While gadolinium has proved to be an extremely effective contrast agent in MRI,
the metallic form of gadolinium can have toxic effects if it is released in the body. It is
therefore necessary to use gadolinium, which is chelated to an organic structure which
can facilitate it’s bioavailability in circulation and excretion. This can be achieved by
using chelating groups such as dodecane tetraacetic acid (DOTA), a well-known
complexing agent that has medical applications as a contrast agent and in cancer
treatment. DOTA is highly effective as chelating gadolinium ions and other metals used
in radioactive molecular imaging modalities such as PET. The structure of DOTA is
shown in Figure 5.
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Figure 5. DOTA, a well-known complexing agent used in cancer imaging

In addition to chelation, a second means of increasing safety is to reduce the
concentration of gadolinium per injection. The use of a targeted imaging agent enables
the contrast agent to concentrate only in the area of interest. This allows for the use of far
less gadolinium-based agent, leading to much lower concentrations in the body.
Furthermore, there have been studies showing that gadolinium is not removed at
wastewater treatment plants, allowing the toxic metal to be released into the aquatic
environment. Through the use of targeted imaging agents, far less gadolinium will be
required resulting in far less gadolinium in the waste stream.27
Thus, in addition to increased brightness and quality of the image provided by a
targeted DOTA-chelated gadolinium contrast agent, the safety of patients is enhanced
along with the quality of downstream aquatic environments.
As alternatives to the use of gadolinium, different metals or inorganic
nanoparticles compatible with MRI can be used to increase the sensitivity of the image.
These have been reviewed by Hyon Bin Na et al. who summarizes the progress of
inorganic MRI contrast agents.28 However, gadolinium contrasts agents continue as the
overwhelming majority of agents used in the clinical setting.27
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1.5.2. PET Imaging Agents
PET detects gamma rays emitted by a positron-emitting radionuclide to create
images. Unlike MRI, which uses a contrast agent to enhance an image, PET is dependent
on an exogenous agent and requires the injection of a radioactive molecule into the
patient in order to obtain an image.18 Although an imaging agent is required, in PET an
extremely small amount of material is needed (on the nmol to pmol scale), which causes
a minimal pharmacological effect on the subject.
PET uses radiopharmaceuticals labelled with positron emitting radionuclides
(such as

11

C,

13

N,

15

O, and

18

F) to obtain the image.14 Radionuclides, which are atoms

with an unstable nucleus, can easily be incorporated into organic molecules and used in
the body for PET imaging. In the past,

18

F has been widely used as a radionuclide for

PET in oncology in the form of fluoro-2-deoxy-glucose (18F-FDG).29

However,

difficulties in the synthesis and the short lifespan of the isotope has encouraged imaging
scientists to find alternative radionuclides.
A radioactive isotope of copper, 64Cu, has been found to have longer lasting decay
characteristics that allow for PET imaging and targeted radiotherapy of cancer.30 The
well-known coordination chemistry of copper allows for it to be used in a wide range of
systems, such as DOTA chelates, that can be linked to peptides and other biologically
relevant compounds.
Radioactive gallium,

68

Ga is another radionucleotide used in PET imaging. Since

radioactive metals are not used in our lab for safety purposes, we use the stable isotopes
of each respective metal in our work. Since the metals’ size is not greatly affected
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between the radionucleotide and stable isotopes, it is assumed that the reactions with the
radioactive isotopes would be similar.
The radioactive half-life of common radionucleotides that can be used in PET
imaging are given in Table 1. The radioactive half-life is defined as the time for half of
the radioactive nuclei to undergo radioactive decay. Consequently, after one half-life,
there will be one half of the original sample remaining. For this reason, longer half-lives
are desired as they will give imaging agents more time to accumulate in the desired area
in the body leading to a more resolved image.
Table 1. Radioactive half-lives of common radionucleotides used in PET31

Isotope

Half-life

11

C

20.364 minutes

13

N

9.965 minutes

O

122.24 seconds

15

18

F

109.77 minutes

64

Cu

12.701 hours

68

Ga

67.71 hours

1.5.3. OMI and CFM Imaging Agents
Optical molecular imaging is a broad term that encompasses many techniques
which are based on the fluorescence of dyes. In molecular imaging these are most often
in the near infrared (NIR) region of the electromagnetic spectrum. In our research, we
rely on confocal fluorescence microscopy (CFM) in order to prove that a TMIA binds
specifically to the particular cancer cell lines that we are targeting.
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CFM is a microscopic technique that provides 3D optical resolution of the
subject. In CFM, white light is used to image all cells and cell components within those
such as the mitochondria and cell walls which may be visualized with great clarity.
Along with white light, a powerful light beam from a laser is used to excite a fluorescent
dye to produce an image of the cell.32 In molecular imaging the dyes used are generally
absorb and emit light in the near infrared (NIR) region of the spectrum.

One

disadvantage to this technique compared to the other techniques mentioned (MRI and
PET) is that it can only be used on the surface of the skin or with invasive surgery, where
cells are removed from the body.
Cyanine 5.5 NHS ester (Cy 5.5) is a reactive dye that has previously been used in
the labeling of amino-groups in peptides, proteins, and oligionucleotides.33 Cy 5.5 is a
far-red and near-infrared emitting dye which is ideal for fluorescence measurements. It
can be used in CFM as to produce an enhanced image in a different wavelength channel
than the white light.

When overlaid, thee two channels will show the entire cell

(generally in black and white) with a fused image of those cells and regions of cells to
which the TMIA has targeted and bound. The chemical structure of a tri-sulfonated form
of Cy 5.5 3S, synthesized by our published methods, is shown in Figure 6.34
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Figure 6. Cy 5.5 NHS Ester Structure

1.5.4. Dual-modal Imaging Agents
Imaging agents are generally utilized in single modal imaging using their
respective imaging techniques such as ferromagnetic and paramagnetic metals for MRI,
radionuclides for PET, and dyes for CFM. To improve imaging, these imaging agents
can also be combined to make dual-modal imaging agents. Dual-modal imaging agents
combine two different imaging agents into one single molecule. This allows two different
imaging methods to be used simultaneously using specialized instrumentation. Dualmodal imaging is a very powerful method that allows for two imaging techniques to
complement each other and provide much more information than one single method.
Pairing modalities such as in PET/CT and PET/MRI in current clinical
applications allow for improved diagnostic sensitivity and specificity in the detection of
diseased regions in the body.32 Single photon emission computed tomography
(SPECT)/CT and MRI/Optical (fluorescence) are two other dual-modal imaging methods
that are used clinically.9

In addition to clinical applications, the largest use in current
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research for dual modal agents is in preclinical research in which animals such as mice
are utilized to test and develop imaging methods and imaging agents.
While it is possible to use two separate imaging agents and achieve enhancements
in each by using dual techniques, there is a distinct advantage of using a single targeted
probe containing imaging agents for each modality. When using two different single
modal agents there can be questions regarding their equivalence of reaching the binding
site. For example, a metal containing agent may have a different uptake, circulation halflife and biodistribution than a dye containing agent. Likewise, metabolism and clearance
are a challenge for imaging agents just as they are for drugs.
By combining these into a single agent, such ambiguity and uncertainly is avoided
and this assures that the circulation, targeting kinetics and pharmacodynamics for each
motif is identical. This is a main advantage of dual-modal imaging agents. A general
schematic of a peptide-based dual-modal TMIA is given in Figure 7.

Figure 7. General schematic of a dual-modal TMIA

In Figure 7, the imaging agents are connected together through a peptide by
attaching a chelated metal or a dye to the side chain of lysine modules, then connecting
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those modules using our patented method.35 Theoretically, these imaging agents would
provide two different imaging methods. For example, one imaging agent may contain a
paramagnetic gadolinium atom that would be suitable as a MRI and one may contain a
radioactive copper-64 atom suitable for PET. This would allow the molecule to be used
for PET/MRI in the detection of cancer, assuming that an appropriate cancer targeting
agent was used.
The images that are created in dual-modal imaging are typically more enhanced
and provide more information than the single modal imaging methods. Because of this,
the imaging methods are said to be complimentary to each other. Figure 8 shows an
image of a 60-year-old patient’s brain with glioblastoma multiforme. The image was
obtained using simultaneous PET/MRI acquisition.36

Figure 8. PET/MRI scan of patient with glioblastoma multiforme36
Reprinted with permission from PET/MRI in cancer patients: first experiences and vision from Copenhagen | SpringerLink
https://link.springer.com/article/10.1007%2Fs10334-012-0357-0. Copyright 2012 Springer.

In the Figure 8, the MRI contrast agent is not targeted, but is able to provide
detailed morphological (spatial) information to the radiologist. The PET agent is targeted
and thus provides the functional information (what is it, or is it a tumor?) However, PET
images are typically very blurry compared to MRI enables determination of exact
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location (where is it, exactly?). Thus, PET and MRI are complementing each other in
dual PET-MRI imaging. Because of the complementary benefit from both agents, dualmodal imaging agents for cancer detection has been the focus of many research programs
with the ultimate goal of improving the sensitivity and contrast of molecular imaging.
1.5.5. Comparison of MRI, PET, and OMI
In molecular imaging methods, the combination of different imaging modalities is
important since each modality has its own set of advantages and disadvantages.37
Complimenting imaging methods with the dual of dual-modal imaging agents adds value
over single-modal imaging. While two different TMIAs could be used in some
circumstances, there is uncertainty whether they would have the same bioavailability in
circulation, or the same concentration at different time points based on the kinetics of
their metabolism and excretion. By combining two different modalities into a single
molecule, this uncertainty is removed.
While OMI utilizes NIR dyes to increase penetration through body tissue over
visible dyes, the depth of imaging is only between 2-5 mm. The main use of OMI is in
cellular research using in vitro studies which use microscopy and other commercial
instruments. In preclinical research, OMI is often used in mice as the depth of penetration
is suitable to study the binding of agents to grafted tumors that are actively growing.
However, as a result of the depth of penetration, clinical use for detection is largely
restricted to melanoma and other types of skin cancer.
Although there are issue with the depth of penetration, there has been a large
surge in both research and translation to human patients in the area of light directed
surgery including the use of NIR-based TMIAs for guiding the removal of cancer tissue
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during surgery.38 Beyond this, OMI is not useful for detecting cancer in internal organs
and it is not possible to image the human brain using OMI due to the lack of penetration..
Another drawback to OMI is non-microscopic animal images can be blurry, making OMI
a low-resolution imaging method.
Unlike OMI, MRI has excellent depth of penetration and is considered a whole
body imaging method. This includes its ability to image the brain, which is encased in
bone, and other organs deep within the body. A second advantage is that MRI provides
excellent spatial resolution, and it is the only technique that can differentiate soft tissues.
It can provide contrast, for example, between a tumor and the organ in which the tumor is
located. The main disadvantage is that MRI is not very sensitive compared to OMI and
PET. A high concentration of gadolinium-based contrast agents is required. Targeting
the agent can improve the contrast ability.
As a complement to both MRI and OMI, PET imaging (which uses targeted
radioactive metals) has excellent depth penetration. Like MRI, PET can be a whole body
technique (including imaging of the brain). PET also has excellent sensitivity as it only
takes a small concentration of the imaging agent to be detected. One disadvantage of
PET is that the resolution is considered low and, like OMI, yields blurry images on the
macro-scale. It is therefore advantageous to combine PET, with its excellent sensitivity,
with MRI, which has great resolution.
1.6. Previous Literature Research in Imaging Agents
In the past, DOTA has been used in the synthesis of imaging agents due to its
strong chelating characteristics which make it beneficial in carrying and holding metals.
Chelation of a metal, such as 64Cu has proved to be extremely useful in PET imaging. In
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early, pioneering work, Zhang and colleagues demonstrated a method where DOTA was
conjugated to the antibody TRC105 and labeled with

64

Cu for PET imaging.39 The

scheme for this reaction is given in Figure 9.

Figure 9. DOTA conjugation with TRC10539

Figure 9 shows how the TRC105 antibody can be coupled to DOTA, which would
go on to chelate copper-64. In the reaction, the NHS ester acts as a leaving group and
reacts with the primary amine of the TRC105. Since TRC105 is a specific monoclonal
antibody, it can be used as a marker for tumor angiogenesis and thus the DOTA-TRC105
is a TMIA in PET for detection of cancerous tumors.39
DOTA can be used in a different fashion, where multiple DOTA complexes are
added to a single antibody. Cai and colleagues demonstrated a method where multiple
DOTA complexes were added to a Cetuximab molecule, which is an antibody that targets
cancer.40 This was done for PET imaging and copper-64 was used as the radioactive
label. Although this method proved to be successful in the clinical evaluation of patients
using PET, the molecule could only be used in PET imaging. The presence of multiple
DOTA groups in this application did not allow for multiple imaging methods to be used
since all the DOTA complexes were chelating copper-64 atoms. The current goal of our
group reaches beyond the work of Cai et al., into the realm of multimodal imaging.
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1.6.1. Previous Literature Research in Dual-modal Imaging Agents
As mentioned, imaging methods can be used simultaneously on specialized
instrumentation by incorporating another type of imaging. Multi-modal imaging agents
emerged in the 1990s, when dual modal imaging methods such as PET/CT came to
clinical use.9,41 In 2013, Suchy and colleagues presented a method that used DOTAderived heterometallic complexes as potential MRI/PET(SPECT) molecular probes.42
This method used Gd3+ as an MRI agent and the cold (non-radioactive) isotopes of Cu2+,
Ga3+, and In3+ as potential PET or SPECT agents. The molecules that were made in this
project were synthesized using the well-known “click” chemistry method.43

The

structure of one of the bimodal MRI/PET(SPECT) molecular imaging agents that was
synthesized in this work shown in Figure 10. It is noted that this agent is not targeted.

Figure 10. Structure of a DOTA-derived chelator coupled with a porphyrin moiety via a peptide
bond to form a non-targeted molecular imaging agent42
Reprinted with permission from Suchý, M.; Bartha, R.; Hudson, R. H. E. “Click” Chemistry toward Bis(DOTA-Derived)
Heterometallic Complexes: Potential Bimodal MRI/PET(SPECT) Molecular Imaging Probes. RSC Adv. 2013, 3 (10), 3249–3259.
https://doi.org/10.1039/C3RA23260C. Copyright 2013 Royal Society of Chemistry.
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In Figure 10, it can be seen that the DOTA moiety is chelating a gadolinium atom
(for MRI) and the porphyrin moiety contains a copper atom (for PET). The use of both
of these metals in the same molecule yields a bimodal imaging agent. Although the
authors did not use a radioactive isotope of copper, which is the only form that would
work with PET, it is suggested that their synthetic method would be similar with the
radioactive isotope.
Similar to our modular approach, both the MRI and PET chelating complexes are
built separately and are combined in a later step the synthetic method used by Suchy et
al. Each metal containing framework built before the metal is added to the complex. This
is due to the fact that once the metal is added, it serves as a protecting group for the
complex and the complex then becomes unreactive. Although this presented a useful
methodology to be used in potential MRI/PET(SPECT) molecular probes, the authors did
not utilize a cancer-targeting group in their synthesis. Thus, these agents are not targeted
molecular imaging agents.
In a related project, Gros et al. present a method to create bimodal contrast agents
for medical imaging, mostly notably in PET/MRI.10 Their methodology was relatively
similar to the method that Suchy et al. used. However, instead of incorporating the metal
atoms in the imaging moieties prior to their combination, metalation was done in the last
steps of the synthesis. Figure 11 shows the addition into the bimodal contrast agent of
the atoms Gd for MRI and Cu for PET .
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Figure 11. Metalation of the imaging agent in the final steps10
Reprinted with permission from Gros, C. P.; Eggenspiller, A.; Nonat, A.; Barbe, J.-M.; Denat, F. New Potential Bimodal Imaging
Contrast Agents Based on DOTA-like and Porphyrin Macrocycles. Med. Chem. Commun. 2011, 2 (2), 119–125.
https://doi.org/10.1039/C0MD00205D. Copyright 2011 Royal Society of Chemistry.

In this method, the synthesis of the desired PET/MRI imaging agent is based on
the selectivity and affinity of the metal chelating groups. Gros et al. demonstrated that
the gadolinium atom has a higher affinity for the DOTA cavity (as it is shown in the
figure) whereas copper matched better for the tetravalent pyrrole based chelator.10 As in
the prior dual modal method, there is no targeting in this scheme.
In 2008, Overoye-Chan et al. presented a method in which a fibrin specific
gadolinium-based MRI contrast agent was made for the detection of thrombus (EP2104R).44 The synthetic approach for creating this multi-Gd containing molecule is
shown in Figure 12.
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Figure 12. Final steps in the synthesis of EP-2104R, a Gd-based MRI contrast agent44
Reprinted with permission from Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng, Q.; Chasse, J. M.;
McMurry, T. J.; Caravan, P. EP-2104R: A Fibrin-Specific Gadolinium-Based MRI Contrast Agent for Detection of Thrombus. J. Am.
Chem. Soc. 2008, 130 (18), 6025–6039. https://doi.org/10.1021/ja800834y. Copyright 2008 American Chemical Society.

This molecule was further studied by another group at Harvard Medical School.45
As it can be seen, the molecule in Figure 12 is not a bimodal imaging agent due to the
fact that the only imaging moieties contained within the molecule are the DOTA-chelated
gadolinium atoms, which are useful in MRI. The goal of the group at Harvard was to
image thrombus using both MRI and PET simultaneously. To achieve this, the MRI
agent EP-2104R was improved upon by partially exchanging the gadolinium metal atoms
from copper-64, which is a suitable PET radionucleotide. Figure 13 shows the synthetic
approach that was used.
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Figure 13. Partial exchange of gadolinium for copper-64 in EP-2104R44
Reprinted with permission from Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng, Q.; Chasse, J. M.;
McMurry, T. J.; Caravan, P. EP-2104R: A Fibrin-Specific Gadolinium-Based MRI Contrast Agent for Detection of Thrombus. J. Am.
Chem. Soc. 2008, 130 (18), 6025–6039. https://doi.org/10.1021/ja800834y. Copyright 2008 American Chemical Society.

The PET-MRI probe did enhance the images of thrombus in rats. However, in
terms of synthesis, the approach is flawed in that the partial metal exchange method that
was used in this approach is not selective and leads to a mixture of dual metal species
with an average reported ration of 5% radiolabel. The result is not a single compound as
there is no way to exactly control the percentage of the gadolinium atoms that are
exchanged.
In the pharmaceutical industry, when a drug is translated to the clinic and
approved by the Food and Drug Administration (FDA), the process is faster when the
drug is a single molecule that can be purified and characterized completely by
spectroscopy. Likewise, in the development of targeted imaging agents it is always
preferable to produce a single, purified and well characterized compound. This presents
a challenge that our group has worked to improve.
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In 2015, Kumar and coworkers at the University of Texas Southwestern Medical
Center (Dallas, Texas) reported a versatile dendritic molecule that can be used for
developing dual-modality imaging agents.37

The molecules created are dendritic

structures with a NOTA core and multiple copies of DOTA groups branching out (Figure
14).

Figure 14. Dual-modal molecular imaging agent design by Kumar et al.37
Reprinted with permission from Kumar, A.; Zhang, S.; Hao, G.; Hassan, G.; Ramezani, S.; Sagiyama, K.; Lo, S.-T.; Takahashi, M.;
Sherry, A. D.; Öz, O. K.; Kovacs, Z.; Sun, X. Molecular Platform for Design and Synthesis of Targeted Dual-Modality Imaging
Probes. Bioconjug. Chem. 2015, 26 (3), 549–558. https://doi.org/10.1021/acs.bioconjchem.5b00028. Copyright 2015 American
Chemical Society.

In an elegant solution to dual modal imaging, this molecule is capable of selective
chelation to gallium and gadolinium based on the different sizes of the NOTA and DOTA
cores. As outlined in Figure 14, the NOTA core is selective for 67,68 Ga3+, which is useful
for SPECT and PET, and the DOTA moieties are selective for Gd3+, which is useful for
MRI. Out of the many imaging agents cited in literature, this dual-modal imaging
approach is possibly the most similar to the molecules synthesized in our lab at RIT.
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Functionally and structurally, the molecule has similar characteristics. However, our
group’s molecules are both smaller and have a simpler synthetic approach.
1.7. Dual-Modal Imaging Instrumentation
In order for dual-modal molecular imaging agents to be most useful, appropriate
dual-modal imaging instrumentation must be available. MILabs currently markets an
imaging module for pre-clinical imaging (of animals) called the U-OI that couples
fluorescence imaging with PET, SPECT, and/or CT for preclinical imaging.46 Although
all of these imaging platforms are not housed in the same instrument, the imaging module
is designed to have a single animal holder that ensures its position does not change in
order to facilitate the exact fusion of images. Animals are typically anesthetized and
immobilized during imaging procedures so this is entirely possible. A picture of the
instrument from the manufacturer’s website is shown in Figure 15.

Figure 15. Duet Optical Imaging module, U-OI from MILabs46

The first MILabs imager is a standalone instrument that is capable of
bioluminescence, fluorescence, and Chrenkov imaging (optical imaging of radiotracers),
and this was then integrated with additional imaging platforms such as PET, SPECT, for

26

dual modal imaging (OMI-PET or CT) with an optional CT built into the latter to provide
true tri-modal imaging (OMI/PET-SPECT/CT).
There are no current dual or tri-modal imaging systems involving fluorescence or
optical molecular imaging as this modality is now largely viewed as mostly useful for
directing real time surgical procedures such as light-directed surgery (LDS) in human
patients as a single modal process.
There are, however, instruments that combine PET and MRI for simultaneous
acquisition. Dual PET instrumentation was first introduced into the clinic in 2008 and
since that time has been reviewed as a significant investment opportunity.47–50 To date, a
number of companies have designed and manufactured preclinical and clinical hybrid
imaging systems for PET-MRI. Some of these instruments are also offered with CT to
provide tri-modal imaging. Bruker manufactures a system that combines MRI and PET
into an instrument for preclinical imaging of mice, the PET/MR 3T.51 This instrument
allows for scientists to test their dual-modal imaging agents in the early stages of
development before moving onto clinical trials. MedisoUSA also makes a preclinical
imaging platform known as the nanoScan Family.52 This instrument combines PET and
SPECT with CT and MRI to allow for nine different imaging combinations.
A number of additional companies including Siemens are ramping up the design
and manufacturing phase or PET-MRI instrumentation, clearly showing a robust growth
rate in preclinical and clinical dual modal imaging systems. However, it is also clearly
apparent that the development of dual modal targeted probes, in particular TMIAs for
PET-MRI, lags the development in instrumentation. This represents a driving force for
the research presented here. In particular, there are no general methods for the synthesis
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of dual modal probes in which a given dual-modal imaging system can be tethered to a
wide variety of targeting agents. It is anticipated that more dual-modal, and possibly trimodal, imaging instrumentation will be developed which will give rise to a pressing need
for dual- and tri-modal TMIAs for a wide variety of cancer types.
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2. Modular Method for Multi-Modal Agents
Our group has developed a modular method to synthesize peptide-based imaging
agents that is based on the principles of peptide chemistry.22,35 DOTA-chelated metals
and imaging dyes are synthesized separately from each other and separate from the
cancer-targeting module. These various imaging groups, used in imaging methods such
as MRI, PET, CFM, etc., are placed on the side chains of amino acids early in the
synthesis. Using amino acids allows the use of well-known peptide coupling methods to
connect different imaging moieties to cancer-targeting agents. In this approach, lysine,
shown in Figure 16, is the amino acid that was used as the basis for each module due to
the primary amine on its side chain. The primary amine can be easily reacted with
imaging modules, to produce stable imaging modules.

Figure 16. Structure of L-lysine, the amino acid commonly used in our targeted molecular
imaging agents

Due to the nature of the well-known features and reactions of peptides, the design
of our imaging agents is simple and the synthesis is practical. There are many advantages
to using peptides over other organic molecules.

Peptides are small and compact,

typically ranging from 1,000 to 3,000 g/mol, which is relatively small for an imaging
agent. The intermediate imaging peptides and final TMIAs can be readily purified by LC
and characterized by LC-Mass Spectroscopy. This enables our group to focus effort on
synthesizing new, improved dyes, developing new TMIAs and less time on developing
and troubleshooting new chemical reactions.
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2.1. Modular Synthetic Approach
Our group’s approach utilizes preformed amino acid-based imaging moieties that
are eventually combined with a cancer-targeting agent in the final steps. The amino acid
moieties are connected to each other using peptide coupling chemistry which forms an
amide bond (peptide bond) from the amine terminus (on the left of each amino acid) to
carbon terminus of the in-coming amino acid. A generalized schematic of our group’s
modular peptide synthetic approach is outlined (Figure 17).
NIR dye 1
or metal 1

Dual Modal TMIA

NIR dye 1
or metal 1

Imaging module 2
TG

Targeting Group
Linker

Fmoc

Linker
Imaging module 1

NIR dye 2
or metal 2

NIR dye 2
or metal 2

Figure 17. General schematic of the modular peptide synthesis of TMIAs

The two imaging agents being connected to each other in this scheme are: a NIR
dye and chelated-metal. These imaging modules (which can be seen as reactants on the
left side of the arrow) are typically synthesized and purified in-house using different
methodologies, depending on the component. It can be seen that both of the imaging
modules in this reaction contain a lysine-based backbone, which allows for the different
components to be connected using peptide coupling methods.
Also shown in Figure 17 is an example of a linker that is used in the synthesis.
Linkers are commonly used in our modular synthetic method to connect the cancertargeting component of the molecule to the imaging component of the molecule. This
allows the targeting group to be put on during the last step in the synthesis.
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A color-coded example of a molecule created in this project using this modular
synthetic methodology is shown in Figure 18. The colors in this figure match the colors
of the components of the TMIA shown in Figure 17.

SMCC Linker
MRI Agent
DOTA-Gd

c(RGDyK)

NIR dye Cy5.5

Figure 18. Color-coded structure of final TMIA, c(RGDyK)-SMCC-dK(Cy5.5)-K(DOTA-Gd)-NH2

A key aspect of the modular synthesis is to apply a given imaging system to a
variety of targeting systems. To exemplify this, a similar color-coded example of a
TMIA created previously in our group using similar modular synthetic methodology, but
employing the PCa PSMA-targeting group DCL as described earlier, with a linker
derived from di-succinyl suberate, DSS, is shown in Figure 19.
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MRI Agent
DOTA-Gd

DSS Linker
DCL targeting group

NIR dye Cy5.5

Figure 19. Color-coded structure of final TMIA, DCL-DSS- dK(Cy 5.5)-K(DOTA-Gd)-NH2

In Figure 19, from the left, the prostate cancer-targeting DCL group is connected
to a lysine module which carries a NIR imaging dye through a DSS linker. This is, in
turn, connected to a second lysine module carrying a DOTA-chelated gadolinium atom.
Each of these components serve a purpose: the DCL targets the cancer, the linker
connects the targeting agent to the imaging modules. The NIRF dye is useful in optical
imaging, and the gadolinium is useful in MRI. When connected together, these four
components combine their separate purposes to form a powerful targeted imaging agent.
There are many different methods that can be used to combine amino acids and
form larger molecules, including linear and convergent synthetic methods.

These

methods each have different orders in which the molecule is built. Our group typically
uses linear synthetic method to build peptides, although convergent methods sometimes
lead to a better yield.
2.1.1. Linear Synthetic Approach
In a linear synthetic method, the desired molecule is synthesized through a
sequence where the product of one reaction is the reactant in the next reaction. In terms
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of the imaging agents that we work with, this method builds the peptide based modules
from the right to left. Polypeptides are created by forming peptide bonds, which involves
the nitrogen (N-terminus) of the first amino acid being bonded to the carbon (C-terminus)
of the second. A schematic of the linear synthetic method of the TMIAs created in our
group is given in Figure 20.
Gd-DOTA

Gd-DOTA

Linker
DSS or SMCC
MRI contrast module

La-DOTA
La-DOTA

PET imaging module
with La placeholder to be
transmetallated after coupling

Gd-DOTA

Gd-DOTA

Targeting
Moiety
Targeting
Moiety

Linker

Linker

c(RGDyK) or DCL

La-DOTA

La-DOTA

Figure 20. General schematic showing linear synthetic method of TMIAs, linker added in a
separate linker step

2.1.2. Convergent Synthetic Approach
In a convergent synthetic method, fragments of the desired molecule are
synthesized separately and brought together at a later stage in the synthesis to form the
target molecule. A schematic for convergent synthesis involving the TMIAs created in
our imaging group is given in Figure 21.
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Gd-DOTA

Targeting
Moiety
Targeting
Moiety

Linker

c(RGDyK) or DCL

DSS or SMCC

dual-modal imaging module
with La placeholder

Linker
Targeting Module

La-DOTA
Gd-DOTA

Targeting
Moiety
Linker

La-DOTA

Figure 21. General schematic showing convergent synthetic method of TMIAs, linker part of
targeting module

In our syntheses of TMIAs, each method (convergent and linear) has shown
advantages and disadvantages depending on the chemistry involved for each particular
TMIA that has been synthesized. This will be described in further detail.
2.2. Identification and Analysis of TMIAs and Intermediates
In this study, reactions were monitored via HPLC-MS instrumentation (Waters)
or UPLC -MS (Shimadzu). This allows for confirmation of the molecule when the
calculated m/z = [M+H]+, [M+2H]2+ and/or [M+3H]3+ peak(s) are present in the positive
electrospray (ES+) spectra. In some instances, for example when sulfonated dyes are
present, these are seen in negative electrospray (ES-) as m/z = [M-H]-, [M-2H]2-, and/or
[M-3H]3-. Key intermediates and final products that were first characterized in our lab
were sent to the Mass Spectrometry Laboratory at University of Illinois School of
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Chemical Sciences for high resolution mass spectroscopy (ESI-HRMS). The masses in
these HRMS are typically accurate to four or five decimal places and can be used to
confidently report that the desired molecule was synthesized.
In most cases, important intermediates and final products were purified by
preparative reverse phase chromatography and assaying collected eluant fractions by
analytical HPLC-MS. Fractions containing pure products (90-100% purity in single
wavelength chromatograms at 264 nm for compounds containing Fmoc group, and 90%
+ purity in total ion chromatograms for compounds with no chromophore groups) were
pooled, concentrated by rotary evaporation under a vacuum, then lyophilized (freezedried) and yields determined from the resultant mass obtained.
TMIA’s synthesized by these methods have been tested for their binding and
selectivity by confocal microscopy in the past, including imaging the TMIA shown in
Figure 18. However, this testing has not taken place (due to the unfortunate passing of
our collaborator in Biology, Dr. Irene Evans) on any of the compounds in this new work.
However, our group has begun a collaboration with Dr. Maureen Ferran from RIT’s
GSOLS and we also collaborate with Roswell Park Cancer Center, and the University of
Rochester. Several of the TMIAs described have been sent to these new collaborators.
These collaborations allow us to test our imaging agents both in vivo and in vitro.
An example of the targeting that is achieved by a TMIA synthesized earlier by
students in our lab is shown in Figure 22. In this study A549 lung cancer cells were
cultured, stained with the dual modal TMIA shown in Figure 18, (prepared earlier by
students in our lab) and imaged by confocal fluorescence microscopy. As described
earlier, the targeting agent c(RGDyK) targets the integrin receptors. The targeting agent
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clearly binds well to the cancer cells as shown by the red imaging. The blue imaging is
created by a stain called NucBlu that specifically stains the nuclei of cells.
In addition, the process of endocytosis can be clearly seen. This is a mechanism
where by xenophobic molecules such as the TMIA, after binding to the receptor, can be
engulfed into the cytoplasm of the cells. The receptor site is regenerated very rapidly,
and addition agents may enter the cell. It is our speculation that this can act as an
amplification scheme to increase the signal. It can be easily deduced then, that since this
is a dual modal agent, that the gadolinium moiety is also contained within the cell and, as
it is covalently linked through the modular system to the dye, that the gadolinium must
therefore also be present in the cells.

Figure 22. Confocal fluorescence microscopy (CFM) of three A549 lung cancer cells targeted by
the TMIA, c(RGDyK)-SMCC-dK(Cy5.5)-K(DOTA-Gd)-NH2 shown in Figure 18. There are about
three cells shown in this image. The red color is a result of targeting by the TMIA, which is
engulfed and accumulates in each cell by the process of endocytosis. The blue color is a result of
staining of the cells by NucBlu, a widely used dye that stains only cell nuclei

Similar to the targeting of A549 cancer cells by c(RGDyK) assayed by CFM, our
collaborators in GSOLS under the direction of Dr. Evans have achieved many images of
prostate cancer (PCa) cells including an aggressive type called C4-2 which express
PSMA (PSMA+) and compared these with atype of PCa cells that are indolent called
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PC3 cells that express low levels of PSMA (PSMA-). An example of a TMIA for this is
B2, synthesized earlier in the Molecular Imaging Laboratory at RIT. The structure is
shown in Figure 23, followed by images of the B2-targeted C4-2 cells in Figure 24 (on
the left and middle) and the control cells , PC3 (on the right).

Figure 23. Structure of B2 showing the single modal DCL-DSS-Lys(Cy5.5)-NH2

Figure 24. Left: Image of about ten C42 (PSMA+) prostate cancer cells illuminated by the TMIA
B-2, DCL-DSS-Lys(Cy5.5). The red color is a result of targeting by the TMIA, which is engulfed
and accumulates in each cell by the process of endocytosis. Middle: Same image of cells in
which the nuclei are lit up with NucBlue. Right: About 20 PC3 (PSMA-) cells in a control
experiment which were treated with the same concentration of TMIA, showing weak binding.

In Figure 24 as noted, the TMIA binds to the (PSMA+) prostate cancer cells and
is engulfed by a process known as endocytosis, illuminating the cells in red. The middle
image are the same cells with a blue channel turned on that shows staining by NucBlu
which specifically illuminates the cell nuclei. On the right are the control PC-3 (PSMA-)
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cells which show very little binding as the expression of PSMA is not elevated in that cell
line. A similar structure was previously reported by the Pomper group at Johns Hopkins
who similarly showed successful targeting by several similar NIR dye-based TMIAs
using DCL-DSS as the targeting motif.20,53
It is important to note that while we have not tested the PCa targeted imaging
agents prepared in this work by CFM, based on the successful targeting of the dual modal
agent using c(RGDyK) that matched earlier successful targeting of single modal agents
both in our lab and in the literature53, it may be predicted that dual modal agents
containing both the dye used in Figures 23 and 24 with the same cell lines will also
produce successful targeting and imaging .
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3. Results and Discussion
3.1. Synthetic Approach to Metal-Containing Imaging Modules
This project focused largely on metal-containing modules that were designed to
be used in MRI and PET. The reaction method that is used to synthesize these metalcontaining modules was carried out using a one-pot synthetic approach, which was
optimized by a fellow lab member, Dana Murphy Soika. The method used to create these
modules is similar regardless of the metal used. Scheme 1 is the reaction scheme
outlining a “one-pot” synthetic method that was used to create the metal-containing
puzzle pieces used in this research project.22

i) NMM, TBTU
ii) Fmoc-(L or D)-Lys-R
iii) Gd(OAc)3 or La(NO3)3
DMF, 70 to 25 °C

(1-3)

Fmoc-(L or D)-Lys-R

Scheme 1. General one-pot synthesis for F-K(M1-DOTA)-R imaging modules, R=NH2 or OH and
M1=Gd or La

There are several conditions that were important to optimize yield. When running
this reaction, DOTA was first dissolved in a dilute solution of DMF and heated to 70°C.
This starting solution should be dilute to discourage any possible di- and tri-substituted
DOTA groups, since mono-substitution is desired. It was found that heating the reaction
mixture aids with solvation of the DOTA, which also maximizes yield of the desired
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product. Once the DOTA is dissolved in the reaction mixture, NMM is added to create a
basic reaction mixture that allows activation of DOTA by TBTU. TBTU, a peptide
coupling reagent, is added at a rate of 0.3 mL/min to also favor mono-substitution on the
DOTA. The lysine is then also added at this slow rate to favor the preferred product.
The metal (Gd or La) is added in the final step and is chelated by the DOTA molecules.
This method is extremely versatile, as it can be used to make many different imaging
modules. In Scheme 1, the R-group is either -OH or -NH2 and M1 is either Gd or La in
the scope of this project. This makes the method useful for both MRI and PET imaging
modules. However, this method could theoretically be used for a countless number of
different metal and amino acid combinations.
3.2. Fmoc Deprotections
The imaging modules discussed in Section 3.1 are made with an amino acid
(lysine) that can be reacted with from the N-terminus or the C-terminus.22

A

fluorenylmethyloxycarbonyl (Fmoc) group is the most commonly used protecting group
in peptide synthesis. It is used to protect the N-terminus of an amino acid from any
unwanted side reactions during other synthetic steps. A deprotection step to remove the
Fmoc group must be carried out in order to further couple other molecules to the Nterminus amine. Scheme 2 is a reaction scheme showing a Fmoc deprotection reaction of
a metal-containing imaging module introduced in Section 3.1.
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DEA
DMF

Scheme 2. General schematic showing simple Fmoc deprotection procedure, F-K(M1-DOTA)NH2 to H-K(M1-DOTA)-NH2

As can be seen in Scheme 2, treatment of the Fmoc group with diethylamine in an
organic solvent successfully removes the group with yields nearing 100%. After the
Fmoc group is removed, the N-terminus of the molecule is ready to further react with
another molecule. Figure 25 shows the mechanism for the Fmoc deprotection.

Figure 25. Mechanism for Fmoc Deprotection
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3.3. NHS Ester Synthesis
N-Hydroxysuccinimide (NHS) is a reagent that is commonly used for activating
acids to prepare them for coupling to amines such as the alpha N-terminus amine when
elongating a peptide chain. The structure of NHS is given (Figure 26).

Figure 26. NHS Structure

NHS is frequently used in biological chemistry to activate carboxylic acids so
they are able to react with amines to form an amide. In this project, the NHS ester was
commonly utilized to couple two different modules together. This includes coupling
dyes to peptide side chains, coupling peptide modules together, and coupling imaging
modules to targeting modules and/or linkers to targeting modules. Scheme 3 is a reaction
scheme showing creation of an NHS ester using TSTU and the reaction with an amine in
a subsequent reaction as outlined in a paper by Wilchek et al.54 .
TSTU, DIPA

primary amine, base

NMP

Scheme 3. General reaction scheme showing formation of NHS ester in first reaction and
coupling in second reaction (R and R’ are different modules)

3.4. Synthesis of Dual-Modal TMIA for Prostate Cancer Using OMI-MRI
While single modal agents based on targeting by DCL have been synthesized, and
one dual modal agent for OMI-PET55, we have found no dual modal agents for OMI-MRI
or PET-MRI that utilize DCL. Thus, it seems appropriate to demonstrate our modular
method to synthesize both of these dual TMIAs.
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In the first set of examples, a dual-

modal TMIA was created for the purpose of imaging prostate cancer using both OMI and
MRI. This was achieved by pairing a Cy 5.5 dye module (for OMI) with a gadoliniumbased imaging module (for MRI) to the prostate cancer targeting agent DCL. Following
the protocol outlined in Section 3.2, the Fmoc group was removed from the F-K(GdDOTA)-NH2 (2) module to create H-K(Gd-DOTA)-NH2 (5), which would be ready to
react with the NHS ester of the Cy 5.5 dye module. Cy 5.5 3S was synthesized using the
procedure published by previous group members Damien Dobson et al.34 The NHS ester
of the Cy 5.5 3S dye was created using the methodology outlined in Section 3.3. The
specific reaction scheme showing the formation of the Cy 5.5 NHS ester can be seen in
Scheme 4. Scheme 4 also shows the Cy 5.5 NHS ester being coupled to the Fmoc
protected lysine to form the desired dye-based imaging module.

TSTU, DIPA
NMP

DIPA
NMP

(4)

Scheme 4. Synthesis of peptide-based dye module , F-dK(Cy5.5 3S)-OH (4)
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Using the same methodology presented Section 3.3, the NHS ester of the FdK(Cy5.5 3S)-OH (4) molecule was created, then reacted with a second module. The
NHS ester, also referred to as the oxysuccinimidyl (OSu) group, F-dK(Cy5.5 3S)-Osu,
was reacted with deprotected gadolinium module for MRI, H-K(Gd-DOTA)-NH2 (5), as
outlined in Scheme 5 to create the dual-modal imaging module for OMI-MRI.

DIPA
DMF, DMSO

(5)
(6)

Scheme 5. Synthesis of Dual-Modal Imaging Module, F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (6)

The Fmoc group of this dual-modal molecule was removed using the method
outlined in Section 3.2 to create a reactive form of the peptide. From here, the molecule
could be reacted with a cancer targeting group in order to create the desired TMIA.
In order to complete the synthesis of the dual modal TMIA for PCa, a convergent
method, developed by Damien Dobson and published earlier by former group members,
was utilized.22
In this convergent method, the DCL was first connected to the linker DSS. This
targeting module was then coupled to the imaging module consisting of the dual modal
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imaging system for OMI-MRI. The reaction in which the targeting module containing
the linker was connected to the dual-modal imaging module is shown in Scheme 6.

TEA
DMSO, DMF

(8)

(7)

Scheme 6. Synthesis of Final Prostate Cancer Targeting Dual-Modal TMIA, DCL-DSS-dK(Cy5.5
3S)-K(Gd-DOTA)-NH2 (8)

Since the linker and targeting group were added as one module in this step, this
presents a convergent synthetic approach. Our group has found that using the convergent
approach most often increases the yield of the TMIA in the final synthetic steps.
The product shown in Scheme 6 has been dubbed as G3 in our Molecular Imaging
Lab and a sample has been supplied to Dr. Ferran in RIT’s GSOLS and to Dr. Nastiuk of
Roswell Park for evaluation in both the CFM imaging and MRI of prostate cancer.
All of the intermediates and final products (4-8) described in Section 3.4 were
purified and assayed as described in Section 2.2.

The details of their synthesis,

purification and identification by LC-MS and HRMS are in in Appendix I.
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3.5. Synthesis of Dual-Modal TMIAs for PET-MRI
Two pseudo PET-MRI agents were next created using a similar methodology as
the OMI-PET agent described in Section 3.4 In these examples, a lanthanum atom was
used as a placeholder for radioactive atoms that could be used in PET. As we are unable
to use radioactive metals in research at RIT (for safety concerns), the nonradioactive form
of these atoms were used in our lab. It is expected that the radioactive forms of these
metals would behave chemically similar—and allow for PET functionality. In order to
make a dual-modal imaging agent for PET-MRI, the challenge was to couple two
different metal containing modules together, and then to differentiate these based on the
stability of one metal over the other metal in dilute acid.
Using the same method outlined in Section 3.1, F-dK(La-DOTA)-OH (1) and FK(Gd-DOTA)-NH2 (2) were synthesized. These modules were coupled together after
removing the Fmoc group from the gadolinium-containing molecule and creating the
NHS ester of the lanthanum-containing molecule. It is important to note that the
lanthanum-containing module contained an alpha carboxylic acid functional group for the
specific purpose of coupling this to the gadolinium module. The order of these molecules
could have been flipped if the lanthanum piece had an amide functional group at the end
and the gadolinium piece had a carboxylic acid group at the end. As the DOTA-Gd
chelate is a very robust complex we typically used that as our C-terminus starting
module. The dipeptide imaging agent was created as shown in Scheme 7.
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TEA

+

DMSO, NMP

(5)

(9)

Scheme 7. Synthesis of Dual-Modal Imaging Molecule for PET-MRI, F-dK(La-DOTA)-K(GdDOTA)-NH2 (9)

After the product in Scheme 7 was synthesized, the Fmoc group was removed
using the deprotection reaction outlined in Section 3.2 in order to prepare it for
conjugation to the cancer targeting group. In this case, instead of the DCL-urea based
targeting group used for the TMIA in Section 3.4, this the cancer-targeting c(RGDyK)
was employed. Although a different cancer-targeting group was used, the same DSS
linker was used for this TMIA as it was discovered to be easier to react than SMCC, a
linker used previously in our lab. As in the case of the targeting module DCL-DSS, the
targeting group was connected to c(RGDyK) before it was added to the dual-modal
imaging molecule. As with the novelty of DCL-DSS, we believe this to be the first
instance of c(RGDyK)-DSS as a targeting module as shown in Scheme 8.
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(11)

TEA
DMF

Scheme 8. Coupling Reaction of c(RGDyK) cancer targeting group and DSS linker

In order to discourage the di-substituted product in Scheme 8, the c(RGDyK) was
added dropwise to the reaction mixture. This technique was found to sufficiently produce
the mono-substituted product. Once this module was created, it was ready for reaction
with the dual-modal imaging molecule previously described and shown in Scheme 7.
After the dual-modal imaging module (in Scheme 7) and the c(RGDyK)-DSS (11)
(in Scheme 8) pieces were synthesized and appropriately purified—and the Fmoc group
was removed from the dual-modal imaging module—the two groups could be combined
to form the final scaffold for the desired TMIAs. The term “scaffold” is used since the
only difference between the desired TMIA and the scaffold is replacing the lanthanum
metal placeholder atom with a gallium or copper atom. This convergent synthesis of the
penultimate final TMIA is shown in Scheme 9. Kelsea Jones, a former group member,
was able to successfully synthesize the compound in Scheme 9. However, Kelsea was
unable to successfully complete the transmetalation step (Scheme 10).56
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(10)

TEA
DMSO, DMF

(12)

(11)

Scheme 9. Coupling of targeting group and linker, c(RGDyK)-DSS (11), with dual-modal
imaging agent to form TMIA scaffold, c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2 (12)

The transmetalation procedure shown in Scheme 10 takes advantage of previous
studies in our laboratory where we learned that lanthanum is labile in dilute TFA (0.2 M),
whereas gadolinium robust and is not labile under these conditions. This provides a
convenient method which is based on the stability of Gd-DOTA coordination bonds
which remain intact while the La-DOTA coordination bonds are labile and broken,
allowing for the lanthanum to be transmetalated. This can occur in a one-step method,
but we find it more effective to use a two-step method that is further described in the
experimental section. The transmetalation step is depicted in Scheme 10.
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CuSO4 or Ga(NO3)3, TFA
H2O

(13), M=Cu
(14), M=Ga

(12)

Scheme 10. Transmetalation of lanthanum atom with potential PET imaging atoms to create final
TMIA, c(RGDyK)-DSS-dK(M-DOTA)-K(Gd-DOTA)-NH2, M=Cu (13) or Ga (14)

All of the intermediates and final products (9-14) described in Section 3.5 were
purified and assayed as described in Section 2.2.

The details of their synthesis,

purification and identification by LC-MS and HRMS are in in Appendix I.
The use of the placeholder metal and the synthetic feature involving a final
transmetalation to metal atom useful for PET imaging provides an important advantage of
the modular method. It is important to consider that the radioactive forms of the metals
copper and gallium, may be avoided in the entire synthesis and that this step could be
performed in the clinic or animal research lab. As the non-radioactive placeholder metal
would not be vulnerable to radioactive decay with short half-lives, it could be stored for
long periods of time and a portion of it be exchanged to the radioactive metal when
needed.

In addition, it could be transported safely to remote testing sites with no

concerns. The transmetalation would be performed easily by the radiologist or their team
right before the TMIA was about to be used in the healthcare setting.
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3.6. Synthesis of Dual-Gadolinium Targeted Contrast Agent for MRI
The contrast of an MRI imaging can be increased with increasing molarity
contrast agent.

A widely used method of achieving this is to place two or more

gadoliniums in a single agent. Among many reports in the literature is a study involving
similar DCL-DSS targeted agents by the Pomper group at Johns Hopkins.

Apart from

this study, there have been few reports of contrast agents for MRI which rely on DCL or
other PSMA inhibitors as targeting moieties. We therefore wished to demonstrate that
the modular method developed in the MIL lab would be a useful means of creating dual
or even multi-Gd TMIAs.22
A dual-gadolinium MRI contrast agent was therefore created by coupling two
Gd imaging molecules, F-dK(Gd-DOTA)-OH (3) and F-K(Gd-DOTA)-NH2 (2), which
were synthesized using the same method outlined in Section 3.1. These modules were
coupled together after removing the Fmoc group from the amide molecule and creating
the NHS ester of the carboxylic acid molecule, as outlined in Scheme 11.

DIPA
DMSO, NMP

(5)

(15)

Scheme 11. Synthesis of Dual-Modal Imaging Molecule for MRI, F-dK(Gd-DOTA)-K(GdDOTA)-NH2 (15)
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After the dual-modal imaging agent in Scheme 11 was synthesized, the Fmoc
group was removed using the deprotection reaction outlined in Section 3.2. At this point,
the molecule could be reacted with a cancer-targeting group. Similar to the synthesis
presented in Section 3.5, c(RGDyK)-DSS (11) was made in a coupling reaction
(identically to Scheme 8) and was attempted to be added to the dual-gadolinium imaging
module. After monitoring the reaction it was determined that the c(RGDyK)-DSS was
not reacting with the dual-gadolinium module. This may have been due to the fact that
the NHS ester of the DSS had been hydrolyzed from residual water. To overcome this, a
linear synthesis was attempted in which the DSS and c(RGDyK) were added separately.
Using this method, which is outlined in Scheme 12, the final dual-gadolinium contrast
agent was created.
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TEA
DMSO, DMF

TEA
DMSO, DMF

(17)

Scheme 12. Coupling of linker, then targeting group in two separate steps to create final TMIA,
c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (17), using a linear synthetic approach

In Scheme 12, it can be seen that a linear synthetic method was used in the
synthesis of this TMIA.

Although the convergent approach described earlier was

attempted the c(RGDyK)-DSS did not effectively couple to the dual-gadolinium module
using the convergent synthetic method. This was attributed to the low solubility of the
di-gadolinium product which required heating, which led to degradation of the sensitive
NHS ester on the DSS moiety. In contrast, the two-step linear method of adding the DSS
first was more effective, as the DSS itself added solubility to the otherwise sparingly
soluble di-gadolinium complex.
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All of the intermediates and final products (15-17) described in Section 3.6 were
purified and assayed as described in Section 2.2.

The details of their synthesis,

purification and identification by LC-MS and HRMS are in in Appendix I.
3.7. Work Towards a Novel Tri-Modal Imaging Agent for OMI-PET-MRI
There are few references of tri-modal imaging agents in literature. This may be
due to the fact that current medical instrumentation does not allow for the simultaneous
acquisition of data using three different methods. However, one of the goals of this
research project was to create a novel tri-modal imaging agent that could potentially be
used in OMI-PET-MRI when technology allows for it. To achieve this, the same dualmodal imaging agent that was synthesized in Scheme 7 (for PET-MRI) was to be
combined with the NHS of the dye created in Scheme 4 (for OMI). This would contain
three different imaging moieties, each useful for a different application, making it a trimodal imaging agent. The reaction in which the previously described PET-MRI imaging
module (after removing the Fmoc group) and the NHS ester of the Cy 5.5 3S dye were
combined is given in Scheme 13.
In this final reaction, the crude reaction mixture was carried out, and quenched
two ways, with water and with butyl amine solution, then and assayed by LC-MS.
Although the un-optimized reaction mixture contained five products, all of which
contained the Cy5.5 dye as shown by the UV-Vis trace of each and a single wavelength
chromatogram at 684 nm, one of these products, with a retention time of 4.89 minutes,
was determined to be the product. The positive and negative ion mass spectra showing
half mass [M-2H]2-/2 in negative ion (ESI-) and third mass [M+3H]3-/3 in positive ion
(ESI+), along with an expanded spectra showing the gadolinium isotope pattern, and along
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with the expected wavelength for Cy5.5 clearly prove that the structure had been
confirmed. This data is shown in the experimental section under the synthesis of
Compound 18 as shown in Scheme 13.

TEA
NMP, DMSO

(10)

(18)

Scheme 13. Synthesis of Tri-Modal Imaging Molecule for OMI-PET-MRI, F-dK(Cy 5.5 3S)dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (18)

Due to time constraints, and notably the inability to return to lab in March 2020
due to the dire global health situation which required social distancing, this crude reaction
mixture was precipitated and remained in the freezer for the duration of the semester.
However, the project was taken to the point where a future student could carry on
this synthesis to completion. The crude reaction mixture could be purified by preparative
HPLC, then the Fmoc group would be deprotected followed by convergent addition of
the either with a targeting group and linker used in this research: c(RGDyK)-DSS and
DCL-DSS in schemes analogous to Schemes 6 and 9 to form a tri-modal imaging agent.
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4. Conclusion
The modular synthetic method used in this project has proven to be useful and
practical in the synthesis of multi-modal TMIAs. This research project demonstrated the
complete synthesis of four (4) novel TMIAs that could be used in dual-modal molecular
imaging. Studies towards tri-modal and other multi-modal imaging agents are still
ongoing, but current results show much promise for the feasibility of these compounds.
The synthesis of the compounds in which lanthanum is used as a placeholder for a
radioactive metal, such as copper-64 or gallium-68, has proved to be a sufficient method.
It is important that the final transmetalation step was worked out in this project, as this is
the step in which the compound becomes useful for PET imaging. This has been an
ongoing project in the molecular imaging laboratory and it is encouraging that the full
synthesis of these molecules was finally worked out.
Although these compounds have been successfully synthesized and characterized
using HPLC-MS and HRMS, their effectiveness as imaging agents still needs to be
tested. Collaborations and plans for both in vivo and in vitro testing have been set up and
will take place in the future. This will allow our group to determine if it is feasible to use
these compounds as TMIAs.
The results and data from this project not only show the synthesis of many novel
TMIAs, but also presents the framework for synthesizing other multi-modal imaging
agents using a modular synthetic approach. Using amino acids with imaging agents
attached to their side chains is a method that has proven to be effective through this
research project and this method could be used in a variety of different imaging
applications.
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5. Experimental Procedures
Chemicals were purchased from Acros Organics (Morris Plains, NY), Alfa Aesar (Ward
Hill, MA), Sigma Aldrich (St. Louis, MO), TCI (Tokyo, Japan), and VWR (Randnor,
PA) and were used as received unless stated otherwise. All chemicals were either
American Chemical Society (ACS) or HPLC grade. Amino acid starting materials were
purchased from Bachem (Bubendorf, Switzerland) and Chem-Impex International Inc.
(Wood Dale, IL). DOTA was purchased from Macrocyclics (Houston, TX).
The HPLC instrument used was an Agilent 1100 with Diode Array Detector and for LCMS a Waters 2695 Alliance HPLC with a Waters 2998 Diode Array Detector and a
Waters 3100 SQ Mass Spectrometer was used. For HPLC the columns used were: an
Agilent XDB C18 column, with dimensions of 3 mm x 100 mm or a Waters XBridge
C18 column 50 mm x 3 mm and 3µ particle size. Mass spectra from this instrument were
recorded at unit resolution with positive and negative switching mode at 35 or 50 V cone
voltages. The flow rate for HPLC-MS was 0.5 mL/min. All aqueous mobile phases for
HPLC are 0.01M ammonium acetate unless otherwise noted. Preparative HPLC (prepHPLC) was carried out with a Waters 600E system controller, and Waters 600 multisolvent delivery system using a 30 mL/min flow rate.
For SPE purification, a 20 g C-18 Sep-pack Varian Mega Bond Elut (20CC/5GRM) SPE
cartridge was utilized for DCL (7) and Gd/La DOTA compounds, and the DOTA
transmetalations utilized a Varian Bond Elut (C18, 12CC/2GRM) SPE cartridge.
Transmetalation studies were monitored using a Shimadzu UHPLC-MS with a Nexera
X2 UHPLC, and LCMS-2020 Mass Spectrometer. A Phenomenex Kinetex EVO C18 150
x 2.1mm column with a 1.7µ particle size was used to assay all transmetalation reactions
and purifications. The flow rate for UHPLC-MS was 0.4 mL/min. The aqueous mobile
phase for UHPLC was 0.01M ammonium acetate and organic phase was methanol with
the gradient described below and in each experimental section.
Aqueous mobile phases for SPE are not buffered unless otherwise noted. The SPE
cartridges were conditioned with their respective organic solvent, then pure DI H2O, then
equilibrated with the initial gradient concentration. Gradients were performed in 5%
increments with 3-10 mL fractions each unless otherwise noted.
High resolution mass spectra (HRMS) were obtained on a Waters Synapt G2Si (School
of Chemical Sciences, University of Illinois at Urbana-Champaign) using the following
parameters: Flow injection at flow rate of 0.1 ml/min, H2O/ACN/0.1% Formic Acid,
positive and negative mode ESI, Cone voltage = 25, capillary voltage = 3.0, ion source
temperature = - 100°C, desolation temperature =180’C, nebulizing gas (N2) flow = 200
L/h, cone gas (N2) flow = 5L/h.
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F-dK(La-DOTA)-OH (1) DOTA (493.6 mg, 0.96 mmol, Macrocyclics) was stirred into
suspension in a solution of NMM (1124.1 mg, 11.1 mmol) in anhydrous DMF (50 mL).
This solution was heated briefly to promote solvation, then allowed to cool back to room
temperature. A solution of TBTU (356.9 mg, 1.11 mmol) in DMF (10 mL) was added to
the reaction flask over 30 minutes with the use of a syringe pump, followed by the
addition of a solution of Fmoc-dLys(H)-OH (300.0 mg, 0.74 mmol) in the same manner.
Immediately following the dropwise addition of this reagent, La(NO3) (481.5 mg, 1.48
mmol) was added to the reaction flask as a crystalline salt. The reaction was stirred
another 25 minutes. Crude product was precipitated from the solution by the addition of
ethyl ether and isolated by decanting the organic solvent after centrifugation. Purification
by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 47.4 mg (7%). MS (HR,
ESI) calc. for C37H47LaN6O11 890.23663, found 891.2431 [M+H]+.
F-K(Gd-DOTA)-NH2 (2) Commercially-available DOTA (692.3 mg, 1.35 mmol) was
stirred into suspension in a solution of NMM (1576.6 mg, 15.6 mmol) in anhydrous DMF
(50 mL). This solution was heated briefly to promote solvation, then allowed to cool back
to room temperature. A solution of TBTU (667.32 mg, 2.08 mmol) in DMF (10 mL) was
added to the reaction flask over 30 minutes with the use of a syringe pump, followed by
the addition of a solution of Fmoc-Lys(H)-NH2 (500.0 mg, 1.04 mmol) in the same
manner. Immediately following the dropwise addition of this reagent, Gd(OAc)3 (844.6
mg, 2.08 mmol) was added to the reaction flask as a crystalline salt. The reaction was
stirred another 25 minutes. Crude product was precipitated from the solution by the
addition of ethyl ether and isolated by decanting the organic solvent after centrifugation.
Purification by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 105.2 mg
(11%). MS (HR, ESI) calc. for C37H48GdN7O10 908.27037, found 909.2765 [M+H]+.
F-dK(Gd-DOTA)-OH (3) Commercially-available DOTA (493.8 mg, 0.964 mmol) was
stirred into suspension in a solution of NMM (1124.5 mg, 11.1 mmol) in anhydrous DMF
(50 mL). This solution was heated briefly to promote solvation, then allowed to cool back
to room temperature. A solution of TBTU (357.0 mg, 1.11 mmol) in DMF (10 mL) was
added to the reaction flask over 30 minutes with the use of a syringe pump, followed by
the addition of a solution of Fmoc-dLys(H)-OH (300.1 mg, 0.741 mmol) in the same
manner. Immediately following the dropwise addition of this reagent, Gd(OAc)3 (495.7
mg, 1.48 mmol) was added to the reaction flask as a crystalline salt. The reaction was
stirred another 25 minutes. Crude product was precipitated from the solution by the
addition of ethyl ether and isolated by decanting the organic solvent after centrifugation.
Purification by SPE (ACN/H2O, 10-60%) yielded the desired product. Yield: 146.8 mg
(22%). MS (HR, ESI) calc. for C37H47GdN6O11 909.25439, found 910.2621 [M+H]+.
F-dK(Cy5.5 3S)-OH (4) Commercially available Fmoc-dLys(H)-OH (28.0 mg, 0.0692
mmol) was dissolved in NMP (3 mL) the solution was cooled to 0°C. To this solution
was added DIPA (89.37 mg, 0.692 mmol) followed by the Cy 5.5 3S-NHS ester. The
reaction was brought to room temperature and was stirred for 1 hour. Crude product was
precipitated by the addition of diethyl ether, and the organic layer was decanted after
centrifugation. Pure product was obtained by preparatory HPLC (ACN/0.01% AmAc, 5-
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80%). Fractions containing pure product were collected, concentrated by rotary
evaporation, and freeze dried. Yield: 14.8 mg, 35%.
H-K(Gd-DOTA)-NH2 (5) Compound 2 (31.1 mg, 0.034 mmol) was dissolved in
anhydrous DMF (5 mL). DEA (50.1 mg, 0.69 mmol) was added to this solution. The
reaction stirred under inert atmosphere one hour. Crude product was precipitated by
addition of ethyl ether to the reaction solution, and organic solvent was decanted after
centrifugation. This process was repeated with ethyl acetate. Product was dried under
vacuum. Yield: 23.5 mg (100%). MS (HR, ESI) calc. for C22H37GdN7O8 686.20229,
found 687.2101 [M+H]+.
F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (6) Compound 4 (10.0 mg, 8.23x10-3 mmol) was
dissolved in DMF (10 mL) and to this solution was added DIPA (10.63 mg 0.0823 mmol)
and TSTU (4.95 mg, 0.0165 mmol). This reaction stirred under argon 1 hour and was
monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine. Upon
completion of this portion of the reaction, crude intermediate product was precipitated by
the addition of EtOAc and diethyl ether, and after centrifugation the organic layer was
decanted and the crude solid dried under argon. Compound 5 (7.34 mg, 0.0107 mmol)
was dissolved in DMSO (1 mL). To this solution was added DIPA (10.63 mg, 0.0823
mmol), followed by the previously isolated product which had been reconstituted in DMF
(5 mL). The reaction ran for 2.5 hours. Crude product was precipitated by the addition of
ethyl ether, and the organic layer was decanted after centrifugation. Pure product was
obtained by SPE (MeOH/H2O, 10-65%). Fractions containing pure product were
collected, concentrated by rotary evaporation, and freeze dried. Yield: 15.5 mg, 100%.
MS (HR, ESI) calc. for C86H106GdN11O21S3 1882.59624, found 942.3064 [M+2H]2+/2.
H-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (7) Compound 6 (15.0 mg , 7.96x10-3) was
dissolved in DMF (3 mL) and to this solution was added diethylamine (11.7 mg, 0.159
mmol). Reaction ran for 3 hours. Crude product was precipitated by the addition of
diethyl ether. This was centrifuged and the organic layer decanted; the crude solid was
triturated with EtOAc to remove Fmoc byproduct, and was again centrifuged and the
organic layer, decanted.
Yield: 13.2 mg, 100%.
MS (HR, ESI) calc. for
2+
C71H96GdN11O19S3 1660.52816, found 831.2723 [M+2H] /2.
DCL-DSS-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 (8) Compound 7 (13.2 mg, 7.95x10-3
mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (20.1 mg,
0.199 mmol). DCL-DSS (9.09 mg, 0.0159 mmol) was dissolved in DMSO (0.2 mL) and
added to the reaction. Reaction was left to stir. After 2.5 hours, TEA (12.1 mg, 0.119
mmol) was added. After 4 hours, additional TEA was added (8.0 mg, 0.0796 mmol). The
reaction was left to react for 12 hours. DCL-DSS (18.18 mg, 0.0318 mmol) was added
after being dissolved in DMSO (0.462 mL). Crude product was precipitated by the
addition of ethyl ether, and the organic layer was decanted after centrifugation. Pure
product was obtained by preparatory HPLC (ACN/H2O, 5-100%). Fractions containing
pure product were collected, concentrated by rotary evaporation, and freeze dried. Yield:
11.3 mg, 67%. MS (HR, ESI) calc. for C91H127GdN14O28S3 2117.73419, found
1059.8750 [M+2H]2+/2.
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F-dK(La-DOTA)-K(Gd-DOTA)-NH2 (9) Compound 1 (32.6 mg, 3.66x10-2 mmol) was
dissolved in NMP (2.5 mL) and to this solution was added DIPA (47.3 mg, 0.366 mmol)
and TSTU (22.0 mg, 7.32 x10-2 mmol). This reaction stirred under argon for 1 hour and
was monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine.
Upon completion of this portion of the reaction, crude intermediate product was
precipitated by the addition of EtOAc and diethyl ether, and after centrifugation the
organic layer was decanted and the crude solid dried briefly under argon. Compound 5
(41.4 mg, 6.04x10-2 mmol) was dissolved in 1.5 mL DMSO. To this solution was added
triethylamine (74.04 mg, 0.732 mmol), followed by the previously isolated crude product
which had been reconstituted in NMP (2 mL). This reaction ran for 1 hour. Crude product
was precipitated by the addition of ethyl ether, and the organic layer was decanted after
centrifugation. Pure product was obtained by SPE (ACN/H2O, 10-60%). Fractions
containing pure product were collected, concentrated by rotary evaporation, and freeze
dried. Yield: 18.8 mg, 33%. MS (HR, ESI) calc. for C59H83GdLaN13O18 1558.42836,
found 780.223 [M+2H]2+/2.
H-dK(La-DOTA)-K(Gd-DOTA)-NH2 (10) Compound 9 (18.8 mg, 1.21x10-2 mmol)
was dissolved in DMF (3 mL) followed by the addition of diethylamine (17.6 mg, 0.24
mmol). Reaction ran for 1 hour. Crude product was precipitated by the addition of diethyl
ether. This was centrifuged and the organic layer decanted; the crude solid was triturated
with EtOAc to remove Fmoc byproduct, and was again centrifuged and the organic layer,
decanted. Yield: 14.8 mg, 92%. MS (HR, ESI) calc. for C44H73GdLaN13O16 1336.36028,
found 1337.369 [M+H]+.
c(RGDyK)-DSS (11) Commercially purchased c(RGDyK) (6.97 mg, 0.0112 mmol) was
dissolved into DMF (1 mL) and to this solution was added TEA (5.69 mg, 0.0562 mmol).
This solution was added dropwise to a separate solution of DSS (4.56 mg, 0.0124 mmol)
that was previously dissolved in DMF (1 mL). Yield: 9.82 mg 100%. MS (HR, ESI)
calc. for C39H56N10O13 872.40283, found 873.4103 [M+H]+.
c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2 (12) Compound 10 (5.00 mg,
3.74x10-3 mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (9.47
mg, 0.0935 mmol). Compound 11 (6.53 mg, 7.4x10-3 mmol) was dissolved in DMSO (1
mL) and added to the reaction. Reaction was left to stir. After 1 hour, TEA (3.79 mg,
0.0374 mmol) was added. After 3 hours, additional TEA (3.79 mg, 0.0374 mmol) was
added. The reaction was left to reaction for 12 hours following the addition of DMSO (1
mL). Butylamine (2.19 mg, 0.0299 mmol) was added to the reaction to quench
remaining compound 11. Crude product was precipitated by the addition of ethyl ether,
and the organic layer was decanted after centrifugation. Yield: 4.1 mg, 52%. MS (HR,
ESI) calc. for C79H124GdLaN22O26 2093.736169, found 1047.8777 [M+2H]2+/2.
c(RGDyK)-DSS-dK(Cu-DOTA)-K(Gd-DOTA)-NH2 (13) Compound 12 (0.91 mg,
4.35x10-4 mmol) was dissolved in aqueous TFA (0.2 M, 1 mL). This solution was stirred
and monitored via UPLC-MS until all of the lanthanum was displaced. After 4 days,
CuSO4 (0.69 mg, 4.35x10-6 mmol) was dissolved in H2O (0.2 mL) and added to the
solution. The reaction was stirred for 30 min. Additional CuSO4 (1.4 mg, 8.70x10-6
60

mmol) was added to the reaction in H2O (0.2 mL). Reaction was stirred for an additional
30 min. Sodium bicarbonate (0.1 M) was added dropwise until the solution was neutral.
Pure product was obtained by SPE (ACN/0.05% aq. TFA, 2-25%). Fractions containing
pure product were collected, concentrated by rotary evaporation, and freeze dried. Yield:
0.68 mg, 77%. MS (HR, ESI) calc. for C79H124CuGdN22O26 2017.75832, found 673.9305
[M+3H]3+/3.
c(RGDyK)-DSS-dK(Ga-DOTA)-K(Gd-DOTA)-NH2 (14) Compound 12 (0.88 mg,
4.20x10-4 mmol) was dissolved in aqueous TFA (0.2 M, 1 mL). This solution was stirred
and monitored via UPLC-MS until all of the lanthanum was displaced. After 24 hours,
this compound was concentrated by rotary evaporation. The compound was dissolved in
distilled H2O (1 mL). Ga(NO3)3•H2O (3.21 mg, 0.0126 mmol) was dissolved in H2O (0.2
mL) and added to the solution. The reaction was stirred for 1 hour. Sodium bicarbonate
(0.1 M) was added dropwise until the solution was neutral. Pure product was obtained by
SPE (ACN/0.05% aq. TFA, 4-25%). Fractions containing pure product were collected,
concentrated by rotary evaporation and freeze dried. Yield: 0.85 mg, 100%. MS (HR,
ESI) calc. for C79H124GaGdN22O26 2023.75429, found 675.5933 [M+3H]3+/3.
F-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (15) Compound 3 (41.7 mg, 0.0459 mmol) was
dissolved in NMP (5 mL) and to this solution was added DIPA (118.6 mg, 0.917 mmol)
and TSTU (27.6 mg, 0.0917 mmol). This reaction stirred under argon 1 hour and was
monitored by HPLC-MS after treating a sample with 0.1% aqueous butylamine. Upon
completion of this portion of the reaction, crude intermediate product was precipitated by
the addition of EtOAc and diethyl ether, and after centrifugation the organic layer was
decanted and the crude solid dried briefly under argon. Compound 5 (31.47 mg, 0.0459
mmol) was dissolved in NMP (1 mL). To this solution was added DIPA (118.59 mg,
0.918 mmol), followed by the previously isolated product which had been reconstituted
in NMP (1 mL). The reaction ran for 3 hours. Crude product was precipitated by the
addition of ethyl ether, and the organic layer was decanted after centrifugation. Pure
product was obtained by SPE (ACN/H2O, 10-60%). Fractions containing pure product
were collected, concentrated by rotary evaporation, and freeze dried. Yield: 23.6 mg,
33%. MS (HR, ESI) calc. for C59H83Gd2N13O18 1577.44501, found 789.7323 [M+2H]2+/2.
H-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (16) Compound 15 (23.6 mg, 0.015 mmol) was
dissolved in NMP (2 mL) followed by the addition of diethylamine (32.8 mg, 0.449
mmol). Reaction ran one hour. Crude product was precipitated by the addition of diethyl
ether. This was centrifuged and the organic layer decanted; the crude solid was triturated
with EtOAc to remove Fmoc byproduct, and was again centrifuged and the organic layer,
decanted. Yield: 20.3 mg, 100%. MS (HR, ESI) calc. for C44H73Gd2N13O16 1355.37693,
found 1356.3833 [M+H]+.
c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2 (17) Compound 16 (1.27 mg,
9.35x10-4 mmol) was dissolved in DMF (2 mL) and to this solution was added TEA (2.36
mg, 0.0234 mmol). Compound 11 (1.63 mg, 1.87x10-3 mmol) was dissolved in DMSO
(0.4 mL) and added to the reaction. The reaction was set to stir. After 1 hour, TEA (4.36
mg, 0.043 mmol) was added to increase the basicity of the solution. Additional 16 (1.27
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mg, 9.35x10-4 mmol) was added. It was determined via HPLC-MS that the coupling
reaction was not progressing. DSS (4.19 mg, 0.0114 mmol) was added to the reaction
mixture. The reaction was heated to 40°C and stirred for 24 hours. Remaining DSS was
removed after precipitating solid by the addition of ethyl ether, and the organic layer was
decanted after centrifugation. This process was repeated with cold ethyl acetate, followed
by warm ethyl acetate. The solid was dried under argon. The following day, the solid
was dissolved in a 1:1 solution of DMSO and DMF (2 mL). c(RGDyK) (6.41 mg, 0.0103
mmol) was added along with TEA (26.15 mg, 0.258 mmol). The solution was stirred for
3 hours. Upon completion of the reaction, crude product was precipitated by the addition
of EtOAc and diethyl ether, and after centrifugation the organic layer was decanted and
the crude solid dried under argon. Pure product was obtained by SPE (ACN/0.05% aq.
TFA, 4-25%). Fractions containing pure product were collected, concentrated by rotary
evaporation and freeze dried. Yield: 14.1 mg, 65%. MS (HR, ESI) calc. for
C79H124CuGdN22O26 2017.75832, found 673.9305 [M+3H]3+/3.
F-dK(Cy5.5 3S)-dK(La-DOTA)-K(Gd-DOTA)-NH2 (18) Compound 4 (14.8 mg,
1.22x10-2 mmol) was dissolved in DMF (10 mL) and to this solution was added DIPA
(15.74 mg 0.122 mmol) and TSTU (7.33 mg, 0.0244 mmol). This reaction stirred under
argon 1 hour and was monitored by HPLC-MS after treating a sample with 0.1% aqueous
butylamine. Upon completion of this portion of the reaction, crude intermediate product
was precipitated by the addition of EtOAc and diethyl ether, and after centrifugation the
organic layer was decanted and the crude solid dried briefly under argon. Compound 10
(4.79 mg, 3.58x10-3 mmol) was dissolved in DMSO (0.5 mL). To this solution was
added TEA (7.25 mg, 0.0717 mmol), followed by the previously isolated product which
had been reconstituted in NMP (2 mL). The reaction ran for 1 hour. Crude product was
precipitated by the addition of ethyl ether, and the organic layer was decanted after
centrifugation.

62

References
(1) American Cancer Society. Cancer Facts & Figures 2019. 2019.
(2) Facts & Figures 2019: US Cancer Death Rate has Dropped 27% in 25 Years
https://www.cancer.org/latest-news/facts-and-figures-2019.html (accessed Jan 14,
2020).
(3) Cancer

Statistics

https://www.cancer.gov/about-cancer/understanding/statistics

(accessed Oct 17, 2019).
(4) What

Is

Cancer?

https://www.cancer.gov/about-cancer/understanding/what-is-

cancer (accessed Oct 17, 2019).
(5) Types of Cancer Treatment https://www.cancer.gov/about-cancer/treatment/types
(accessed Oct 17, 2019).
(6) Huang, Z. A Review of Progress in Clinical Photodynamic Therapy. Technol
Cancer Res Treat 2005, 4 (3), 283–293.
(7) van Straten, D.; Mashayekhi, V.; de Bruijn, H. S.; Oliveira, S.; Robinson, D. J.
Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and
Future

Directions.

Cancers

(Basel)

2017,

9

(2).

https://doi.org/10.3390/cancers9020019.
(8) Cancer Prevention & Early Detection Facts & Figures 2019-2020. American Cancer
Society 2019.
(9) Seaman, M. E.; Contino, G.; Bardeesy, N.; Kelly, K. A. Molecular Imaging Agents:
Impact on Diagnosis and Therapeutics in Oncology. Expert Rev Mol Med 2010, 12,
e20. https://doi.org/10.1017/S1462399410001511.
(10) Gros, C. P.; Eggenspiller, A.; Nonat, A.; Barbe, J.-M.; Denat, F. New Potential
Bimodal Imaging Contrast Agents Based on DOTA-like and Porphyrin
Macrocycles.

Med.

Chem.

Commun.

2011,

2

(2),

119–125.

https://doi.org/10.1039/C0MD00205D.
(11) Healy, C. F.; Murray, J. G.; Eustace, S. J.; Madewell, J.; O’Gorman, P. J.;
O’Sullivan, P. Multiple Myeloma: A Review of Imaging Features and Radiological
Techniques.

Bone

Marrow

Research

https://doi.org/10.1155/2011/583439.

63

2011,

2011,

1–9.

(12) Khalkhali, I.; Mena, I.; Diggles, L. Review of Imaging Techniques for the Diagnosis
of Breast Cancer: A New Role of Prone Scintimammography Using Technetium99m

Sestamibi.

Eur

J

Nucl

Med

1994,

21

(4),

357–362.

https://doi.org/10.1007/BF00176577.
(13) Lecouvet, F. E.; Talbot, J. N.; Messiou, C.; Bourguet, P.; Liu, Y.; de Souza, N. M.
Monitoring the Response of Bone Metastases to Treatment with Magnetic
Resonance Imaging and Nuclear Medicine Techniques: A Review and Position
Statement by the European Organisation for Research and Treatment of Cancer
Imaging Group. European Journal of Cancer 2014, 50 (15), 2519–2531.
https://doi.org/10.1016/j.ejca.2014.07.002.
(14) Paans, A. M. J.; Waarde, A. van. Positron Emission Tomography. Methods 1999, 27
(3), 193–194. https://doi.org/10.5170/CERN-2006-012.363.
(15) Wu, H.; Huang, J. PEGylated Peptide-Based Imaging Agents for Targeted
Molecular Imaging. Curr. Protein Pept. Sci. 2016, 17 (6), 582–595.
(16) Weissleder, R. Molecular Imaging in Cancer. Science 2006, 312 (5777), 1168–1171.
https://doi.org/10.1126/science.1125949.
(17) Zako, T.; Nagata, H.; Terada, N.; Utsumi, A.; Sakono, M.; Yohda, M.; Ueda, H.;
Soga, K.; Maeda, M. Cyclic RGD Peptide-Labeled Upconversion Nanophosphors
for Tumor Cell-Targeted Imaging. Biochemical and Biophysical Research
Communications 2009, 381 (1), 54–58. https://doi.org/10.1016/j.bbrc.2009.02.004.
(18) Shokeen, M.; Anderson, C. J. Molecular Imaging of Cancer with Copper-64
Radiopharmaceuticals and Positron Emission Tomography (PET). Acc Chem Res
2009, 42 (7), 832–841. https://doi.org/10.1021/ar800255q.
(19) Danhier, F.; Le Breton, A.; Préat, V. RGD-Based Strategies To Target Alpha(v)
Beta(3) Integrin in Cancer Therapy and Diagnosis. Mol. Pharmaceutics 2012, 9
(11), 2961–2973. https://doi.org/10.1021/mp3002733.
(20) Banerjee, S. R.; Foss, C. A.; Castanares, M.; Mease, R. C.; Byun, Y.; Fox, J. J.;
Hilton, J.; Lupold, S. E.; Kozikowski, A. P.; Pomper, M. G. Synthesis and
Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the ProstateSpecific Membrane Antigen (PSMA). J Med Chem 2008, 51 (15), 4504–4517.
https://doi.org/10.1021/jm800111u.
64

(21) Maresca, K. P.; Hillier, S. M.; Femia, F. J.; Keith, D.; Barone, C.; Joyal, J. L.;
Zimmerman, C. N.; Kozikowski, A. P.; Barrett, J. A.; Eckelman, W. C.; Babich, J.
W. A Series of Halogenated Heterodimeric Inhibitors of Prostate Specific
Membrane Antigen (PSMA) as Radiolabeled Probes for Targeting Prostate Cancer.
J. Med. Chem. 2009, 52 (2), 347–357. https://doi.org/10.1021/jm800994j.
(22) Schmitthenner, H.; Dobson, D.; Jones, K.; Akporji, N.; Soika, D.; Nastiuk, K.;
Hornak, J. Modular Synthesis of DOTA‐Metal Based PSMA Targeted Imaging
Agents

for

MRI

and

PET

of

Prostate

Cancer.

Chemistry

2019.

https://doi.org/10.1002/chem.201903390.
(23) Chang, S. S. Overview of Prostate-Specific Membrane Antigen. Rev Urol 2004, 6
(Suppl 10), S13–S18.
(24) Fortuin, A.; De Rooij, M.; Zamecnik, P.; Haberkorn, U.; Barentsz, J. Molecular and
Functional Imaging for Detection of Lymph Node Metastases in Prostate Cancer.
International Journal of Molecular Sciences 2013, 14 (7), 13842–13857.
https://doi.org/10.3390/ijms140713842.
(25) Magnetic

Resonance

Imaging

(MRI)

https://www.nibib.nih.gov/science-

education/science-topics/magnetic-resonance-imaging-mri (accessed Nov 5, 2019).
(26) Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and
Applications | Chemical Reviews https://pubs.acs.org/doi/abs/10.1021/cr980440x
(accessed Oct 28, 2019).
(27) Rogowska, J.; Olkowska, E.; Ratajczyk, W.; Wolska, L. Gadolinium as a New
Emerging Contaminant of Aquatic Environments. Environmental Toxicology and
Chemistry 2018, 37 (6), 1523–1534. https://doi.org/10.1002/etc.4116.
(28) Na, H. B.; Song, I. C.; Hyeon, T. Inorganic Nanoparticles for MRI Contrast Agents.
Advanced

Materials

2009,

21

(21),

2133–2148.

https://doi.org/10.1002/adma.200802366.
(29) Rohren, E. M.; Turkington, T. G.; Coleman, R. E. Clinical Applications of PET in
Oncology.

Radiology

2004,

https://doi.org/10.1148/radiol.2312021185.

65

231

(2),

305–332.

(30) Anderson, C. J.; Ferdani, R. Copper-64 Radiopharmaceuticals for PET Imaging of
Cancer: Advances in Preclinical and Clinical Research. Cancer Biother.
Radiopharm. 2009, 24 (4), 379–393. https://doi.org/10.1089/cbr.2009.0674.
(31) Nudat 2 https://www.nndc.bnl.gov/nudat2/chartNuc.jsp (accessed Oct 30, 2019).
(32) Pierce, M. C.; Javier, D. J.; Richards-Kortum, R. Optical Contrast Agents and
Imaging Systems for Detection and Diagnosis of Cancer. Int J Cancer 2008, 123
(9), 1979–1990. https://doi.org/10.1002/ijc.23858.
(33) Cyanine5.5 NHS ester https://www.lumiprobe.com/p/cy55-nhs-ester.
(34) Dobson, D. E.; Mahoney, E. R.; Mach, T. P.; LeTourneau, R. J.; Schmitthenner, H.
F. Pentamethine Sulfobenzoindocyanine Dyes with Low Net Charge States and
High

Photostability.

Photochem.

Photobiol.

Sci.

2020,

19

(1),

56–65.

https://doi.org/10.1039/C9PP00445A.
(35) Schmitthenner, H. F.; Beach, S.; Weidman, C.; Barrett, T. Modular Imaging Agents
Containing Amino Acids and Peptides. US20150038672A1, February 5, 2015.
(36) PET/MRI in cancer patients: first experiences and vision from Copenhagen |
SpringerLink

https://link.springer.com/article/10.1007%2Fs10334-012-0357-0

(accessed Nov 4, 2019).
(37) Kumar, A.; Zhang, S.; Hao, G.; Hassan, G.; Ramezani, S.; Sagiyama, K.; Lo, S.-T.;
Takahashi, M.; Sherry, A. D.; Öz, O. K.; Kovacs, Z.; Sun, X. Molecular Platform
for Design and Synthesis of Targeted Dual-Modality Imaging Probes. Bioconjug.
Chem. 2015, 26 (3), 549–558. https://doi.org/10.1021/acs.bioconjchem.5b00028.
(38) New technology could “light up” cancer cells during surgery and improve cancer
surgery outcomes: First human clinical trials underway - Purdue University
https://www.purdue.edu/newsroom/releases/2014/Q4/new-technology-could-lightup-cancer-cells-during-surgery-and-improve-cancer-surgery-outcomes-first-humanclinical-trials-underway.html (accessed May 5, 2020).
(39) Zhang, Y.; Hong, H.; Engle, J. W.; Bean, J.; Yang, Y.; Leigh, B. R.; Barnhart, T. E.;
Cai, W. Positron Emission Tomography Imaging of CD105 Expression with a
64Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA. PLOS ONE
2011, 6 (12), e28005. https://doi.org/10.1371/journal.pone.0028005.

66

(40) Cai, W.; Chen, K.; He, L.; Cao, Q.; Koong, A.; Chen, X. Quantitative PET of EGFR
Expression in Xenograft-Bearing Mice Using 64Cu-Labeled Cetuximab, a Chimeric
Anti-EGFR Monoclonal Antibody. Eur J Nucl Med Mol Imaging 2007, 34 (6), 850–
858. https://doi.org/10.1007/s00259-006-0361-6.
(41) Burke, B. P.; Cawthorne, C.; Archibald, S. J. Multimodal Nanoparticle Imaging
Agents: Design and Applications. Philosophical Transactions of the Royal Society
A: Mathematical, Physical and Engineering Sciences 2017, 375 (2107), 20170261.
https://doi.org/10.1098/rsta.2017.0261.
(42) Suchý, M.; Bartha, R.; Hudson, R. H. E. “Click” Chemistry toward Bis(DOTADerived)
Molecular

Heterometallic
Imaging

Complexes:

Probes.

RSC

Potential
Adv.

Bimodal

2013,

3

MRI/PET(SPECT)
(10),

3249–3259.

https://doi.org/10.1039/C3RA23260C.
(43) Hein, C. D.; Liu, X.-M.; Wang, D. Click Chemistry, a Powerful Tool for
Pharmaceutical

Sciences.

Pharm

Res

2008,

25

(10),

2216–2230.

https://doi.org/10.1007/s11095-008-9616-1.
(44) Overoye-Chan, K.; Koerner, S.; Looby, R. J.; Kolodziej, A. F.; Zech, S. G.; Deng,
Q.; Chasse, J. M.; McMurry, T. J.; Caravan, P. EP-2104R: A Fibrin-Specific
Gadolinium-Based MRI Contrast Agent for Detection of Thrombus. J. Am. Chem.
Soc. 2008, 130 (18), 6025–6039. https://doi.org/10.1021/ja800834y.
(45) pubmeddev; al, U. R., et. Bimodal thrombus imaging: simultaneous PET/MR
imaging with a fibrin-targeted dual PET/MR probe--feasibility study in rat model. PubMed - NCBI https://www.ncbi.nlm.nih.gov/pubmed/21177389 (accessed Nov
14, 2019).
(46) beheer. Advancing Optical Imaging Translational Power with Multimodal Imaging.
MILabs.
(47) PMR

launches

analysis

report

on

PET

MRI

Market

https://www.biospectrumasia.com/news/41/15065/pmr-launches-analysis-report-onpet-mri-market.html (accessed Mar 25, 2020).
(48) Research, R. M. Hybrid Imaging Systems Market investigated in the latest research
https://www.whatech.com/market-research/it/638802-hybrid-imaging-systemsmarket-demand-and-forecasts-to-2026 (accessed Mar 25, 2020).
67

(49) Medical Hybrid Imaging System Market Research on Medical Hybrid Imaging
System Market 2019 and Analysis to 2025 – Monroe Scoop.
(50) PET/MRI Enters the U.S. Market https://www.itnonline.com/article/petmri-entersus-market-0 (accessed Mar 25, 2020).
(51) Preclinical PET/MR Imaging Solution | Bruker PET/MR 3T | Bruker
https://www.bruker.com/products/preclinical-imaging/nuclear-molecularimaging/petmr-3t.html?gclid=CjwKCAjw3bzBRBhEiwAgnnLClij4GyCvETJZl5yH5h1XOIEAghGu2KUszTZnmrquGqioLbw
URWCBBoCy4cQAvD_BwE (accessed Mar 25, 2020).
(52) Preclinical Imaging Systems: nanoScan PET, SPECT, CT, MRI 3T and 1T
http://www.medisousa.com/preclinical/nanoscan (accessed Mar 25, 2020).
(53) Chen, Y.; Dhara, S.; Banerjee, S. R.; Byun, Y.; Pullambhatla, M.; Mease, R. C.;
Pomper, M. G. A Low Molecular Weight PSMA-Based Fluorescent Imaging Agent
for Cancer. Biochem Biophys Res Commun 2009, 390 (3), 624–629.
https://doi.org/10.1016/j.bbrc.2009.10.017.
(54) Wilchek, M.; Knudsen, K. L.; Miron, T. Improved Method for Preparing NHydroxysuccinimide Ester-Containing Polymers for Affinity Chromatography.
Bioconjugate Chem. 1994, 5 (5), 491–492. https://doi.org/10.1021/bc00029a018.
(55) Banerjee, S. R.; Pullambhatla, M.; Byun, Y.; Nimmagadda, S.; Foss, C. A.; Green,
G.; Fox, J. J.; Lupold, S. E.; Mease, R. C.; Pomper, M. G. Sequential SPECT and
Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality
Inhibitor of the Prostate-Specific Membrane Antigen. Angew Chem Int Ed Engl
2011, 50 (39), 9167–9170. https://doi.org/10.1002/anie.201102872.
(56) Jones, K. Modular Synthesis of Targeted Molecular Imaging Agents for MRI, PET,
and PET-MRI of Cancer. Theses 2019.

68

Appendix I. HPLC-MS and HRMS Results
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1200

Mass spectrum of 1 at 1.6 min, 891.66 m/z [M+H]+
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1429.68

1400

m/z

HRMS of pure 1 product, 891.2431 m/z [M+H]+
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19_07_03_NS_F-K(DOTA-Gd)-NH2_b
Compound 2 F-K(Gd-DOTA)-NH2
19_07_03_NS_F-K(DOTA-Gd)-NH2_after_ether_crash_2

3: Diode Array
263
Range: 1.018

3.62

8.0e-1
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6.0e-1
4.0e-1
2.0e-1
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Time
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7.00

Single wavelength chromatogram of 2 at 263 nm for crude reaction mixture
19_07_03_NS_F-K(DOTA-Gd)-NH2_b
19_07_03_NS_F-K(DOTA-Gd)-NH2_after_ether_crash_2 435 (3.617) Cm (426:459)
206.53
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nm

UV-Vis19_07_03_NS_F-K(DOTA-Gd)-NH2_b
spectrum of 2 at 3.6 min with characteristic peak at 263 nm for Fmoc protecting group
19_07_03_NS_F-K(DOTA-Gd)-NH2_after_ether_crash_2 113 (3.855) Cm (106:114)
678.87
4.95e5
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1184.35

1364.42
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Mass spectrum of 2 at 3.6 min, 909.96 m/z [M+H]+
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1400

m/z

19_07_03_NS_F-K(DOTA-Gd)-NH2_b
19_07_03_NS_F-K(DOTA-Gd)-NH2_after_ether_crash_2 113 (3.855) Cm (106:114)
909.96
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Expanded parent ion from spectrum above, displaying Gd isotope pattern of 2

HRMS of pure 2 product displaying Gd isotope pattern, 909.2765 m/z [M+H]+
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19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1
Compound 3 F-dK(Gd-DOTA)-OH
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1

3: Diode Array
263
Range: 6.198e-1

1.57

6.0e-1
5.0e-1
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Time
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Single wavelength chromatogram of 3 at 263 nm for crude reaction mixture
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1 190 (1.575) Cm (176:204) 3: Diode Array
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UV-Vis19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1
spectrum of 3 at 1.6 min with characteristic peak at 263 nm for Fmoc protecting group
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1 45 (1.525) Cm (44:48)
631.02
631.86

1: Scan ES+
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1200

Mass spectrum of 3 at 1.6 min, 909.51 m/z [M+H]+
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1447.88

1400

m/z

19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1
19_11_14_NS_F-dK(DOTA-Gd)-OH_monitor_1 45 (1.525) Cm (44:48)

1: Scan ES+
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Expanded parent ion from spectrum above, demonstrating Gd isotope pattern of 3

HRMS of pure 3 product displaying Gd isotope pattern, 910.2621 m/z [M+H]+
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20_02_12_NS_F-K(Cy 55 3S)-OH_Prep30full
20_02_12_NS_F-K(Cy 55Compound
3S)-OH_Prep30full
4 F-dK(Cy5.5 3S)-OH

3: Diode Array
680
Range: 2.563

5.29

2.5
2.0
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5.0e-1
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Time
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Single wavelength
of 4 at 680 nm for pure product
20_02_12_NS_F-K(Cy
55 chromatogram
3S)-OH_Prep30full
20_02_12_NS_F-K(Cy 55 3S)-OH_Prep30full 667 (5.550) Cm (667:671)
684.53

3: Diode Array
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nm

UV-Vis
spectrum of 4 at 5.355min
with characteristic peak around 684 nm for Cy 5.5 dye
20_02_12_NS_F-K(Cy
3S)-OH_Prep30full
20_02_12_NS_F-K(Cy 55 3S)-OH_Prep30full 156 (5.328) Cm (154:156)
606.57

100

1: Scan ES1.59e6
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Mass spectrum of 4 at 5.3 min, 1214.65 m/z [M-H]-, 606.57 m/z [M-2H]2-/2
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Compound 5 H-K(Gd-DOTA)-NH2
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2 158 (1.308) Cm (134:162)

1.918
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19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
UV-Vis
spectrum of 5 at 1.1 min, demonstrating lack of characteristic Fmoc absorption
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2

1: Scan ES+
685_687
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Time
8.00

XIC for 5 of mass range 685 to 687 m/z
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2 32 (1.097) Cm (32:37)
685.38

100

2: Scan ES6.59e4
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Mass spectrum of 5 at 1.1 min, 685.4 m/z [M+H]+
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1200

m/z

19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2
19_12_04_NS_H-K(DOTA-Gd)-NH2_1hr_monitor_2 32 (1.079) Cm (31:34) 1: Scan ES+
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Expanded parent ion of 5 from spectrum above, displaying Gd isotope pattern

HRMS of pure 5 product displaying Gd isotope pattern, 687.2101 m/z [M+H]+

78

F-dK(Cy55)-K(DOTA-Gd)-NH2_55
F-dK(Cy55)-K(DOTA-Gd)-NH2_55
Compound 6 F-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2 3: Diode Array
3.40
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Range: 2.322
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F-dK(Cy55)-K(DOTA-Gd)-NH2_55
Single wavelength chromatogram of 6 at 680 nm for purified product
F-dK(Cy55)-K(DOTA-Gd)-NH2_55 417 (3.467) Cm (417:418)
684.53

3: Diode Array
6.73e-1
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UV-Vis
spectrum of 6 at 3.4 min with characteristic peak around 683 nm for Cy 5.5 dye
F-dK(Cy55)-K(DOTA-Gd)-NH2_55
F-dK(Cy55)-K(DOTA-Gd)-NH2_55 103 (3.512) Cm (98:103)

1: Scan ES+
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Mass spectrum of 6 at 3.4 min, 943.32 m/z [M+2H]2+/2
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m/z

F-dK(Cy55)-K(DOTA-Gd)-NH2_55
F-dK(Cy55)-K(DOTA-Gd)-NH2_55 103 (3.512) Cm (98:103)

1: Scan ES+
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Expanded parent ion of 6 from spectrum above, displaying Gd isotope pattern

HRMS of pure 6 product, 942.3064 m/z [M+2H]2+/2
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Compound 7 H-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2
H-dK(Cy55)-K(DOTA-Gd)-NH2_60mins_monitor_c
H-dK(Cy55)-K(DOTA-Gd)-NH2_61mins_monitor_b

3: Diode Array
680
Range: 1.866
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Single wavelength chromatogram of 7 at 680 nm showing product
H-dK(Cy55)-K(DOTA-Gd)-NH2_60mins_monitor_c
H-dK(Cy55)-K(DOTA-Gd)-NH2_61mins_monitor_b 212 (1.758) Cm (204:225)
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UV-Vis
spectrum of 7 at 1.8 min with characteristic peak around 683 nm for Cy 5.5 dye
H-dK(Cy55)-K(DOTA-Gd)-NH2_60mins_monitor_c
H-dK(Cy55)-K(DOTA-Gd)-NH2_61mins_monitor_b 54 (1.833) Cm (51:59) 1: Scan ES+
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Mass spectrum of 7 at 1.8 min, 831.52 m/z [M+2H]2+/2
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m/z

H-dK(Cy55)-K(DOTA-Gd)-NH2_60mins_monitor_c
H-dK(Cy55)-K(DOTA-Gd)-NH2_61mins_monitor_b 54 (1.833) Cm (51:59) 1: Scan ES+
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Expanded parent ion of 7 from spectrum above, demonstrating Gd isotope pattern

HRMS of pure 7 product displaying Gd isotope pattern, 831.2723 m/z [M+2H]2+/2
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Compound 8 DCL-DSS-dK(Cy5.5 3S)-K(Gd-DOTA)-NH2

Single wavelength chromatogram of 8 at 680 nm for pure product
mAU(x1,000)
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UV-Vis spectrum of 8 at 2.9 min with characteristic peak around 683 nm for Cy 5.5 dye
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nm

Inten.(x100,000)
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Mass spectrum of 8 at 2.9 min, 1058 m/z [M-2H]2-, 705 m/z [M-3H]3-/3

HRMS of pure 8 product showing Gd isotope pattern, 1059.8750 m/z [M+2H]2+/2
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m/z

Compound 9 F-dK(La-DOTA)-K(Gd-DOTA)-NH2

Single wavelength chromatogram of 9 on UPLC-MS at 263 nm for pure product
mAU(x100)
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UV-Vis spectrum of 9 at 3.3 min with characteristic peak at 265 nm for Fmoc protecting group
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nm

Inten.(x1,000,000)
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Mass spectrum of 9 at 3.3 min, 1560 m/z [M+H]+, 780 m/z [M+2H]2+/2

HRMS of pure 9 product showing Gd isotope pattern 780.2230 m/z [M+2H]2+
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m/z

Compound 10 H-dK(La-DOTA)-K(Gd-DOTA)-NH2
205

mAU(x1,000)
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UV-Vis spectrum of 10 at 0.5 min, demonstrating lack of characteristic Fmoc absorption
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XIC of crude reaction mixture for 10 showing conversion of starting material (780 m/z) to product (669
m/z)
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2.25

Inten.(x10,000,000)
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Mass spectrum of 10 at 0.5 min, 669 m/z [M+2H]2+/2

HRMS of pure 10 product displaying Gd isotope pattern 1337.3690 m/z [M+H]+
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m/z

Compound 11 c(RGDyK)-DSS
19_09_23_NS_c(RGDyK)-DSS_BAquench_2
19_09_23_NS_c(RGDyK)-DSS_BAquench_2

1: Scan ES+
832_833
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XIC of mass range 832 to 833 m/z for compound 11
19_09_23_NS_c(RGDyK)-DSS_BAquench_2
19_09_23_NS_c(RGDyK)-DSS_BAquench_2 87 (2.964) Cm (87:94)
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1: Scan ES+
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Mass spectrum of 11 in 0.1% aq. butylamine at 3.0 min, 832.19 m/z buylamine adduct of product, 416.83
half mass of butylamine adduct
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HRMS of pure 11 product, 873.4103 m/z [M+H]+
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20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b
Compound 12 c(RGDyK)-DSS-dK(La-DOTA)-K(Gd-DOTA)-NH2

%

20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b Sm (Mn, 1x3)
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20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b
XIC of mass range 1047 to 1050 m/z for compound 12
20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b 111 (3.787) Cm (106:112)
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Mass spectrum of 12 at 3.8 min, 1046.96 m/z [M+2H]2+, 698.63 m/z [M+3H]3+/3
20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b
20_02_21_NS_c(RGDyK)-DSS-dK(DOTA-La)-K(DOTA-Gd)-NH2_pure_5_70_b 111 (3.787) Cm (106:112)
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Expanded parent ion of 12 from spectrum above, displaying Gd isotope pattern
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HRMS of pure 12 product displaying Gd isotope pattern, 1047.8730 m/z [M+2H]2+/2
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Compound 13 c(RGDyK)-DSS-dK(Cu-DOTA)-K(Gd-DOTA)-NH2
(x100,000)
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XIC of mass 674 m/z for compound 13
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Mass spectrum of 13 at 1.4 min, 1011 m/z [M+2H]2+, 674 m/z [M+3H]3+/3
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HRMS of pure 13 product displaying Gd isotope pattern, 673.5975 m/z [M+3H]3+/3
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Compound 14 c(RGDyK)-dK(Ga-DOTA)-K(Gd-DOTA)-NH2
(x100,000)
1:676.00(+)
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

4.0

4.5

min

XIC of mass 676 m/z for compound 14
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Mass spectrum of 14 at 0.9 min, 1014 m/z [M+2H]2+, 676 m/z [M+3H]3+/3
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1300 m/z

HRMS of pure product 14, 675.5933 [M+3H]3+/3
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Compound 15 F-dK(Gd-DOTA)-K(Gd-DOTA)-NH2
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA

3: Diode Array
263
Range: 5.906
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Single wavelength chromatogram of 15 at 263 nm for crude reaction mixture
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA 350 (2.908) Cm (343:404)
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UV-Vis spectrum
of 15 at 2.9 min with characteristic peak around 263 nm for Fmoc protecting group
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA 81 (2.759) Cm (81:96)
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Mass spectrum of 15 at 2.9 min, 1577.97 m/z [M+H]+, 789.71 m/z [M+2H]2+/2

97

19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA
19_12_05_NS_F-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_3hr_BA 81 (2.759) Cm (81:96)
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Expanded parent ion of 15 from spectrum above, displaying Gd isotope pattern

HRMS of pure 15 product displaying Gd isotope pattern,789.7323 m/z [M+2H]2+
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19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min
Compound 16 H-dK(Gd-DOTA)-K(Gd-DOTA)-NH2
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min 181 (1.500) Cm (151:181)
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UV-Vis
spectrum of 16 at 1.5 min, demonstrating lack of characteristic Fmoc absorption
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min Sm (Mn, 1x3)
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1: Scan ES+
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XIC of mass range 678 to 680 m/z for compound 16
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min 44 (1.491) Cm (30:44)
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Mass spectrum of 16 at 1.5 min, 678.19 m/z [M+2H]2+/2
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m/z
1400

19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min
19_12_09_NS_H-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_60min 45 (1.525) Cm (29:45)
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Expanded parent ion from spectrum above of 16, displaying Gd isotope pattern

HRMS of pure 16 product displaying Gd isotope pattern, 1356.3833 m/z [M+H]+
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Compound 17 c(RGDyK)-DSS-dK(Gd-DOTA)-K(Gd-DOTA)-NH2
19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr

%

19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr Sm (Mn, 1x3)
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XIC of mass range 1057 to 1059 m/z for compound 17
19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr
19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr 30 (1.011) Cm (24:30)
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Mass spectrum of 17 at 1.0 min, 1057.46 m/z [M+2H]2+, 705.03 m/z [M+3H]3+/3
19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr
19_11_13_NS_c(RGDyK)-DSS-dK(DOTA-Gd)-K(DOTA-Gd)-NH2_BA_1hr 30 (1.011) Cm (24:30)
1057.46
7.97e4
100
1058.73

%

1056.65

1055.75

1038.71

1040

1066.18

1049.52

1040.16

0

1059.69

1045

1060.26

1055.21

1050

1055

1070.03 1074.32

1060

1065

1078.25

1070

1075

1080

m/z

Expanded parent ion of 17 from spectrum above, displaying Gd isotope pattern
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HRMS of pure 17 product displaying Gd isotope pattern, 1057.3828 m/z [M+2H]2+/2
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Compound 18 F-dK(Cy5.5 3S)-dK(La-DOTA)-K(Gd-DOTA)-NH2
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
1.2

3: Diode Array
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Range: 1.235
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Single wavelength chromatogram of 18 at 684 nm showing product in crude reaction mixture. The product
18 is the peak at 4.89 minutes.
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b 589 (4.900) Cm (579:598)
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UV-Vis spectrum of 18 at 4.9 min, showing absorption peak
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
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20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b

1: Scan ESTIC
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XIC of compound 18, the product is the peak at 4.88 min
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Time
8.00

20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b 143 (4.883) Cm (141:145)
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ESI- mass
spectra of product peak at 4.9 min at showing product 18 at 1265.73, [M+2H]2+/2
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b 143 (4.883) Cm (141:146)
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Expanded region of ESI- mass spectra of 18 showing Gd isotope pattern

20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b

20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b 141 (4.832) Cm (140:146)
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Mass spectrum of 18 at 4.8 min, 1268.22 m/z [M+2H]2+ displaying Gd isotope pattern
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20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b
20_02_20_NS_F-K(Cy55)-K(DOTA-La)-K(DOTA-Gd)-NH2_25hr_mon_b 141 (4.832) Cm (140:145)
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Mass spectrum of 18 at 4.8 min, 845.86 m/z [M+3H]3+ displaying Gd isotope pattern. This result taken with
the result from [M+2H]2+ is evidence that the compound 18 was indeed formed in the final coupling
reaction
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